Investigators	Year	n	Study design	Stent type	AVF or AVG	Primary patency (%)	(months)

3 M	6 M	12 M

Vogel and Parise [12]	2004	53	Retrospective	SMART	AVG	77 (61–93)	51 (34–67)	20 (12–27)	mean 8.9

Vogel and Parise [14]	2005	25	Prospective, Non-randomized	SMART	AVG	88 (75–100)	67 (48–86)	41 (21–61)	mean 8.2

Pan et al. [21]	2005	12	Retrospective	Wallstent, Jostent	AVF	92 ± 8	81 ± 12	31 ± 17	n/a

Liang et al. [22]	2006	23	Observational	Wallstent, nitinol	AVG	69 ± 9	41 ± 10	30 ± 10	n/a

Maya and Allon [23]	2006	14	Prospective, Non-randomized	Wallstent, SMART, Protégé, Fluency	AVG	48	19	n/a	median 2.8

Chan, M.R. et al. [24]	2008	211	Retrospective	SMART	AVG	69	25	n/a	median 4.4

Current study	2011	50	Prospective, Observational	SMART	Both	79 ± 9	51 ± 15	27 ± 16	median 3.8

		25			AVF	80 ± 10	65 ± 16	32 ± 21	median 5.2

		25			AVG	76 ± 15	28 ± 22	19 ± 17	median 2.9

Investigators	Year	n	Study design	Stent type

Vogel and Parise [12]	2004	53	Retrospective	SMART

Vogel and Parise [14]	2005	25	Prospective, Non-randomized	SMART

Pan et al. [21]	2005	12	Retrospective	Wallstent, Jostent

Liang et al. [22]	2006	23	Observational	Wallstent, nitinol

Maya and Allon [23]	2006	14	Prospective, Non-randomized	Wallstent, SMART, Protégé, Fluency

Chan, M.R. et al. [24]	2008	211	Retrospective	SMART

Current study	2011	50	Prospective, Observational	SMART

		25

		25


Component (g/kg)	Group

NFD	HFD	GR	SV0.5	SV2

Casein	210	265	265	265	265

L-cystine	3	4	4	4	4

Corn starch	280	–	–	–	–

Maltodextrin	50	160	150	155	140

Sucrose	325	90	90	90	90

Lard	20	310	310	310	310

Soybean oil	20	30	30	30	30

Cellulose	37.15	65.5	65.5	65.5	65.5

Mineral mixture1	35	48	48	48	48

Vitamin mixture2	15	21	21	21	21

Calcium phosphate, dibasic	2	3.4	3.4	3.4	3.4

Choline bitartrate	2.75	3	3	3	3

Yellow food color	0.1	–	–	–	–

Blue food color	–	0.1	0.1	0.1	0.1

Garcinia cambogia extract of 60% (–)-hydroxycitric acid	–	–	10	–	–

Solidago virgaurea var. gigantea 10% ethanol extract	–	–	–	5	20

Total (g)	1000	1000	1000	1000	1000

Energy (kcal/g)	3.7	5.1	5.1	5.1	5.1

Protein (% of kcal)	20.1	18.3	18.3	18.3	18.3

Carbohydrate (% of kcal)	69.8	21.4	21.4	21.4	21.4

Fat (% of kcal)	10.2	60.3	60.3	60.3	60.3

Component (g/kg)	Group

NFD	HFD	GR	SV0.5	SV2

Casein	210	265	265	265	265

L-cystine	3	4	4	4	4

Corn starch	280	–	–	–	–

Maltodextrin	50	160	150	155	140

Sucrose	325	90	90	90	90

Lard	20	310	310	310	310

Soybean oil	20	30	30	30	30

Cellulose	37.15	65.5	65.5	65.5	65.5

Mineral mixture1	35	48	48	48	48

Vitamin mixture2	15	21	21	21	21

Calcium phosphate, dibasic	2	3.4	3.4	3.4	3.4

Choline bitar	2.75	3		3	3

Component (g/kg)	Group

NFD	HFD	GR	SV0.5	SV2

trate			3

Yellow food color	0.1	–	–	–	–

Blue food color	–	0.1	0.1	0.1	0.1

Garcinia cambogia extract of 60% (–)-hydroxycitric acid	–	–	10	–	–

Solidago virgaurea var. gigantea 10% ethanol extract	–	–	–	5	20

Total (g)	1000	1000	1000	1000	1000

Energy (kcal/g)	3.7	5.1	5.1	5.1	5.1

Protein (% of kcal)	20.1	18.3	18.3	18.3	18.3

Carbohydrate (% of kcal)	69.8	21.4	21.4	21.4	21.4

Fat (% of kcal)	10.2	60.3	60.3	60.3	60.3


Well	Biochemical test	Result

2	D-amygdalin (AMY)	−

4	Phosphatidylinositol phospholipase C (PIPLC)	−

5	D-xylose (dXYL)	−

8	Arginine dihydrolase 1 (ADH1)	+

9	Beta-galactosidase (BGAL)	−

11	Alpha-glucosidase (AGLU)	−

13	Ala-Phe-Pro arylamidase (APPA)	−

14	Cyclodextrin (CDEX)	−

15	L-aspartate arylamidase (AspA)	−

16	Beta galactopyranosidase (BGAR)	−

17	Alha-mannosidase (AMAN)	−

19	Phosphatase (PHOS)	+

20	Leucine arylamidase (LeuA)	+

23	L-proline arylamidase (ProA)	−

24	Beta glucuronidase (BGURr)	−

25	Alpha-galactosidase (AGAL)	−

26	L-pyrrolidonyl-arylamidase (PyrA)	−

27	Betaglucuronidase (BGUR)	−

28	Alanine arylamidase (AlaA)	−

29	Tyrosine arylamidase (TyrA)	−

30	D-sorbitol (dSOR)	−

31	Urease (URE)	−

32	Polymixin b resistance (POLYB)	+

37	D-galactose (dGAL)	+

38	D-ribose (dRIB)	+

39	L-lactate alkalinization (ILATk)	−

42	L-actose (LAC)	−

44	N-acetyl-d-glucosamine (NAG)	+

45	D-maltose (dMAL)	+

46	Bacitracin resistance (BACI)	+

47	Novobiocin resistance (NOVO)	+

50	Growth in 6.5% NaCl (NC 6.5)	+

52	D-mannitol (dMAN)	−

53	D-mannose (dMNE)	+

54	Methyl-B-D-glucopyranoside (MBdG)	+

56	Pullulan (PUL)	−

57	D-raffinose (dRAF)	−

58	O/129 resistance (comp. vibrio) (O129R)	−

59	Salicin (SAL)	−

60	Saccharose/sucrose (SAC)	+

62	D-trehalose (dTRE)	+

63	Arginine dihydrolase 2 (ADH2s)	+

64	Optochin resistance (OPTO)	+

Well	Biochemical test	Result

45	D-maltose (dMAL)	+

46	Bacitracin resistance (BACI)	+

47	Novobiocin resistance (NOVO)	+

50	Growth in 6.5% NaCl (NC 6.5)	+

52	D-mannitol (dMAN)	−

53	D-mannose (dMNE)	+

54	Methyl-B-D-glucopyranoside (MBdG)	+

56	Pullulan (PUL)	−

57	D-raffinose (dRAF)	−

58	O/129 resistance (comp. vibrio) (O129R)	−

59	Salicin (SAL)	−

60	Saccharose/sucrose (SAC)	+

62	D-trehalose (dTRE)	+

63	Arginine dihydrolase 2 (ADH2s)	+

64	Optochin resistance (OPTO)	+


Treatment	Number of pregnant females	Number of implantation sites	Number of viable fetuses	Total number of resorption sites

Group A	19/20	9.96 ± 1.83∗	9.85 ± 1.67∗∗	4∗

Group B	18/20	9.19 ± 1.05∗	8.73 ± 1.12∗∗	5

Group C (control)	17/10	7.17 ± 0.60	6.23 ± 1.05	6

Treatment

Group A

Group B

Group C (control)

Number of pregnant females	Number of implantation sites	Number of viable fetuses	Total number of resorption sites

19/20	9.96 ± 1.83∗	9.85 ± 1.67∗∗	4∗

18/20	9.19 ± 1.05∗	8.73 ± 1.12∗∗	5

17/10	7.17 ± 0.60	6.23 ± 1.05	6


Gene	Nucleotide (%) a	Amino acid (%) b

Pol 1a	92.5	93.2

Pol 1ab	92.9	95.0

Spike	94.2	94.2

Envelope	87.2	91.0

Membrane	89.0	91.2

Nucleocapsid	86.7	87.1


Gene	ORFs

	A. nidulans	A. niger

palA	AN4351	119792

palB	AN0256	171058

palC	AN7560	48740

palF	AN1844	Not found*

palH	AN6886	120044

palI	AN4853	52449

vps32/snf7	AN4240	136905

pacC	AN2855	47049


Variable	Category	Frequency	Percent

Distance of health institution	< 1 h	100	13.9

≥ 1 h	622	86.2

Accessibility of pharmacy	Yes	198	27.4

No	524	72.6

Presence of health profession in the family	Yes	56	7.2

No	666	92.8

Presence of medication at home	Yes	105	14.5

No	617	85.5

Previous experience of SMP	Yes	402	55.7

No	320	44.3

Peer/family pressure	Yes	226	31.3

No	496	68.7

Member of health insurance	Yes	448	62.0

No	274	38.0


Group	Dose (mg/kg)	Malondialdehyde (MDA, nmol/mg pro)	Superoxidase Dismutase (SOD, U/mg pro)	Total Antioxidant Capacity (T-AOC, U/mg pro)	Glutathione Peroxidase (GSH-PX, U/mg pro)	Catalase (CAT, U/mg pro)

NC		1.40 ± 0.18	383.26 ± 15.34	4.30 ± 0.23	213.22 ± 15.56	51.07 ± 3.78

		3.09 ± 0		2.46 ± 0.2	147.68 ± 19.88 *	23.79 ± 3.91


Name	Oligonucleotide (5′ to 3′)

C286A Forward	GCT TTG ATT CTT GCA GTT GCC ATT GCA GTC AAC AGT CG

C286A Reverse	CGA CTG TTG ACT GCA ATG GCA ACT GCA AGA ATC AAA GC

C286S Forward	GCT TTG ATT CTT GCA GTT TCC ATT GCA GTC AAC AGT CG

C286S Reverse	CGA CTG TTG ACT GCA ATG GAA ACT GCA AGA ATC AAA GC

C295A Forward	CAG TCG AAG AAG GGC TGG GCA GAA GAA AAA GC

C295A Reverse	GCT TTT TCT TCT GCC CAG CCC TTC TTC GAC TG

Name

C286A Forward

C286A Reverse

C286S Forward

C286S Reverse

C295A Forward

C295A Reverse

Oligonucleotide (5′ to 3′)

GCT TTG ATT CTT GCA GTT GCC ATT GCA GTC AAC AGT CG

CGA CTG TTG ACT GCA ATG GCA ACT GCA AGA ATC AAA GC

GCT TTG ATT CTT GCA GTT TCC ATT GCA GTC AAC AGT CG

CGA CTG TTG ACT GCA ATG GAA ACT GCA AGA ATC AAA GC

CAG TCG AAG AAG GGC TGG GCA GAA GAA AAA GC

GCT TTT TCT TCT GCC CAG CCC TTC TTC GAC TG


	Control	Low P	Moderate P	High P	P-values

N resorption proficiency (mg g−1)


Domain 1: Skills for Chronic Condition Self-Management	Domain 2: Skills for Self-Advocacy and Health Care Utilization

Do you fill a prescription if you need to?	Do you fill out the medical history form, including a list of your allergies?

Do you know what to do if you are having a bad reaction to your medications?	Do you keep a calendar or list of medical and other appointments?

Do you pay or arrange payments for your medications?	Do you tell the doctor or nurse what you are feeling?

Do you take medications correctly and on your own?	Do you ask questions of the doctor, nurse or clinic staff?

Do you reorder medications before they run out?	Do you make a list of questions before the doctor’s visit?

Do you call the suppliers when there is a problem with the equipment?	Do you request the accommodations & support you need at school or work?

Do you order medical equipment before they run out?	Do you apply for a job or work or vocational services?

Do you arrange payment for the medical equipment and supplies?	Do you get financial help with school or work?

Do you call the doctor’s office to make an appointment?	Do you help plan or prepare meals/food?

Do you call the doctor about unusual changes in your health?	Do you help keep home/room clean or clean up after meals?

Do you apply for health insurance if you lose your current coverage?	Do you use neighborhood stores and services?

Do you know what your health insurance covers?	Do you use community support services or advocacy services when you need them?

Do you manage your money and budget household expenses?

Do you reorder medications before they run out?

Domain 1: Skills for Chronic Condition Self-Management	Domain 2: Skills for Self-Advocacy and Health Care Utilization

Do you fill a prescription if you need to?	Do you fill out the medical history form, including a list of your allergies?

Do you know what to do if you are having a bad reaction to your medications?	Do you keep a calendar or list of medical and other appointments?

Do you pay or arrange payments for your medications?	Do you tell the doctor or nurse what you are feeling?

Do you take medications correctly and on your own?	Do you ask questions of the doctor, nurse or clinic staff?

Do you reorder medications before they run out?	Do you make a list of questions before the doctor’s visit?

Do you call the suppliers when there is a problem with the equipment?	Do you request the accommodations & support you need at school or work?

Do you order medical equipment	Do you apply for a job or wo

 before they run out?	rk or vocational services?

Do you arrange payment for the medical equipment and supplies?	Do you get financial help with school or work?

Do you call the doctor’s office to make an appointment?	Do you help plan or prepare meals/food?

Do you call the doctor about unusual changes in your health?	Do you help keep home/room clean or clean up after meals?

Do you apply for health insurance if you lose your current coverage?	Do you use neighborhood stores and services?

Do you know what your health insurance covers?	Do you use community support services or advocacy services when you need them?

Do you manage your money and budget household expenses?

Do you reorder medications before they run out?


Bachaur	Gangatiri	Kherigarh	Kenkatha	Ponwar	Shahabadi	Purnea	Mewati	Gaolao	Hariana	Ongole

0.000											Bachaur

0.008	0.000										Gangatiri

0.009	0.010	0.000									Kherigarh


Simulation set up	Time	Memory

Genome Simulationa	One subclone with 100 SVs	0.98 h	9.1 Gb

	One subclone with 200 SVs	1.34 h	9.9 Gb

	One subclone with 300 SVs	1.73 h	11.6 Gb

	Two subclones with 100 SVs	1.03 h	9.5 Gb

	Three subclones with 100 SVs	1.28 h	10.2 Gb

Read generationb	Mixing reads from 2 subclones and 1 normal genome (392 M reads)	2.76 h	6.2 Gb

	GC-bias Introduction (130 M reads)	4.10 h	2.5 GB


Self-report risk assessment	Positive ADHD screen % (n)	Negative ADHD screen % (n)	Χ2 (df = 1)	Odds ratio (95% confidence interval)

Any illness or injury, or any other medical condition?	51.3 (20)	31.7 (45)	5.10*	2.27 (1.10 to 4.66)

Taking, supposed to be taking, or need any tablets/medication?	19.5 (8)	15.6 (22)	0.35	1.31 (0.54 to 3.21)

Consumed alcohol in the last 24 hours?	28.2 (11)	26.8 (38)	0.03	1.08 (0.49 to 2.37)

Dependent on drugs or any other substances?	25.6 (10)	9.2 (13)	7.50**	3.42 (1.37 to 8.57)

Ever tried to harm yourself?	23.1 (9)	7.7 (11)	7.32**	3.57 (1.36 to 9.39)

Experiencing any mental health problems or depression?	23.1 (9)	6.4 (9)	9.35**	4.37 (1.60 to 11.94)

Require any help with reading/writing?	10.3 (4)	2.8 (4)	3.96	3.91 (0.93 to 16.44)

Custody officer risk assessment

Detainee appears to be injured or unwell?	20.5 (8)	11.3 (16)	2.22	2.02 (0.79 to 5.14)

Detainee is in need of a Doctor or other Health Care Professional?	20.0 (6)	11.3 (13)	1.58	1.96 (0.68 to 5.69)

Appears to have taken/be under the influence of alcohol/drugs/any other substance?	23.1 (9)	12.8 (18)	2.55	2.05 (0.84 to 5.01)

Detainee has indications of self harm?	17.9 (7)	5.7 (8)	6.03*	3.64 (1.23 to 10.77)

Self-report risk assessment	Positive ADHD screen % (n)	Negative ADHD screen % (n)	Χ2 (df = 1)	Odds ratio (95% confidence interval)

Any illness or injury, or any other medical condition?	51.3 (20)	31.7 (45)	5.10*	2.27 (1.10 to 4.66)

Taking, supposed to be taking, or need any tablets/medication?	19.5 (8)	15.6 (22)	0.35	1.31 (0.54 to 3.21)

Consumed alcohol in the last 24 hours?	28.2 (11)	26.8 (38)	0.03	1.08 (0.49 to 2.37)

Dependent on drugs or any other substances?	25.6 (10)	9.2 (13)	7.50**	3.42 (1.37 to 8.57)

Ever tried to harm yourself?	23.1 (9)	7.7 (11)	7.32**	3.57 (1.36 to 9.39)

Experiencing any mental health problems or depression?	23.1 (9)	6.4 (9)	9.35**	4.37 (1.60 to 11.94)

Require any help with reading/writing?	10.3 (4)	2.8 (4)	3.96	3.91 (0.93 to 16.44)

Custody officer risk assessment

Detainee appears to be injured or unwel	20.	11.3 	2.

l?	5 (8)	(16)	22	2.02 (0.79 to 5.14)

Detainee is in need of a Doctor or other Health Care Professional?	20.0 (6)	11.3 (13)	1.58	1.96 (0.68 to 5.69)

Appears to have taken/be under the influence of alcohol/drugs/any other substance?	23.1 (9)	12.8 (18)	2.55	2.05 (0.84 to 5.01)

Detainee has indications of self harm?	17.9 (7)	5.7 (8)	6.03*	3.64 (1.23 to 10.77)


Cancer site	Mediastinal-both	Mediastinal-both & Supra-both	Mediastinal-both & Supra-left	Mediastinal-left

Breast

3DCRT	0.86	0.84	0.85	0.91

VMAT	2.05	1.82	1.89	1.93

Lung

3DCRT	0.76	0.80	0.78	0.74

VMAT	1.29	1.11	1.17	1.55

Esophagus

3DCRT	0.94	0.98	1.06	0.90

VMAT	1.01	1.12	1.15	1.00

Stomach

Cancer site	Mediastinal-both	Mediastinal-both & Supra-both	Mediastinal-both & Supra-left	Mediastinal-left

3DCRT	0.92	0.91	0.92	0.93

VMAT	0.93	0.93	0.93	0.92

Thyroid

3DCRT	0.89	0.61	0.62	0.93

VMAT	0.88	0.67	0.79	0.93

Bone sarcoma

3DCRT	0.88	0.87	0.82	0.88

VMAT	0.62	0.58	0.60	0.63

Soft tissue sarcoma

3DCRT	0.89	0.83	0.83	0.90

VMAT	0.75	0.65	0.69	0.78

All cancers

3DCRT	0.82	0.82	0.82	0.86

VMAT	1.59	1.36	1.43	1.63


Trait	Region	SNP	Closest gene	P value	Alleles ancestral>derived

Hair shape	1q21	rs11803731	<underline>TCHH</underline>	3 × 10−12	A>T

Hair shape	2q12	rs3827760	<underline>EDAR</underline>	3 × 10−119	A>G

Hair shape	10p14	rs17143387	GATA3	4 × 10−8	T>G

Hair shape	16p11	rs11150606	<underline>PRSS53</underline>	7 × 10−9	T>C

Beard thickness	2q12	rs365060	EDAR	1 × 10−15	G>C

Beard thickness	4q12	rs4864809	LNX1	1 × 10−8	A>G

Beard thickness	6q21	rs6901317	PREP	4 × 10−8	G>T

Beard thickness	7q31	rs117717824	FOXP2	1 × 10−8	G>T

Eyebrow thickness	3q22	rs112458845	FOXL2	4 × 10−10	G>A

Monobrow	2q36	rs2218065	PAX3	5 × 10−8	A>G

Hair greying	6p25	rs12203592	IRF4	3 × 10−13	C>T

Hair colour	5p13	rs183671	SLC45A2	2 × 10−59	T>G

Hair colour	6p25	rs12203592	IRF4	1 × 10−13	C>T

Hair colour	11q14	rs598952	TYR	2 × 10−8	T>A

Hair colour	15q13	rs12913832	HERC2/OCA2	5 × 10−104	A>G

Hair colour	15q21	rs1426654	SLC24A5	1 × 10−18	G>A

Balding	10q22	rs2814331	GRID1	4 × 10−9	C>T

Balding	Xq12	rs4258142	AR/EDA2R	2 × 10−8	C>T

Trait	Region

Hair shape	1q21

Hair shape	2q12

Hair shape	10p14

Hair shape	16p11

Beard thickness	2q12

Beard thickness	4q12

Beard thickness	6q21

Beard thickness	7q31

Eyebrow thickness	3q22

Monobrow	2q36

Hair greying	6p25

Hair colour	5p13

Hair colour	6p25

Hair colour	11q14

Hair colour	15q13

Hair colour	15q21

Balding	10q22

Balding	Xq12


Flexion angle and side	Involved	95% Confidence intervals	Uninvolved	95% Confidence intervals	P value

Torque at 30 degrees	1.09	0.87–1.31	1.17	0.98–1.36	P = 0.45

Torque at 60 degrees	1.75	1.4–2.1	2.09	1.77–2.41	P = 0.08

Flexion angle and side	Involved	95% Confidence intervals	Uninvolved	95% Confidence intervals	P value

Torque at 60 degrees	1.75	1.4–2.1	2.09	1.77–2.41	P = 0.08


Intra-nuclear body	GO Term	Description	E-Value

Nucleolus	GO:0042254	Ribosome biogenesis and assembly	1.80E-19

	GO:0022613	Ribonucleoprotein complex biogenesis and assembly	3.30E-15

	GO:0016072	rRNA metabolic process	3.30E-14

	GO:0006364	rRNA processing	3.30E-14

	GO:0009059	Macromolecule biosynthetic process	2.90E-08

	GO:0043228	Non-membrane-bound organelle	3.30E-08

	GO:0043232	Intracellular non-membrane-bound organelle	3.30E-08

	GO:0006412	Translation	5.70E-08

	GO:0009058	Biosynthetic process	1.20E-06

PML nuclear body	GO:0006950	Response to stress	6.10E-09

	GO:0006974	Response to DNA damage stimulus	1.70E-08

	GO:0009719	Response to endogenous stimulus	2.30E-08

	GO:0050896	Response to stimulus	4.00E-07

	GO:0006281	DNA repair	4.40E-05

	GO:0042770	DNA damage response, signal transduction	5.90E-05

	GO:0007049	Cell cycle	1.40E-03

	GO:0006464	Protein modification process	1.60E-03

	GO:0022402	Cell cycle process	2.70E-03

Nuclear Speckle	GO:0016071	mRNA metabolic process	1.20E-61

	GO:0006397	mRNA processing	4.80E-61

	GO:0008380	RNA splicing	1.20E-58

	GO:0005681	Spliceosome	1.90E-38

	GO:0006396	RNA processing	5.80E-34

	GO:0030529	Ribonucleoprotein complex	1.90E-26

	GO:0003723	RNA binding	2.00E-25

	GO:0016070	RNA metabolic process	1.70E-06

	GO:0000377	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	4.10E-06

	GO:0000398	Nuclear mRNA splicing, via spliceosome	4.10E-06

Intra-nuclear body

Nucleolus

PML nuclear body

Nuclear Speckle

GO Term	Description	E-Value

GO:0042254	Ribosome biogenesis and assembly	1.80E-19

GO:0022613	Ribonucleoprotein complex biogenesis and assembly	3.30E-15

GO:0016072	rRNA metabolic process	3.30E-14

GO:0006364	rRNA processing	3.30E-14

GO:0009059	Macromolecule biosynthetic process	2.90E-08

GO:0043228	Non-membrane-bound organelle	3.30E-08

GO:0043232	Intracellular non-membrane-bound organelle	3.30E-08

GO:0006412	Translation	5.70E-08

GO:0009058	Biosynthetic process	1.20E-06

GO:0006950	Response to stress	6.10E-09

GO:0006974	Response to DNA damage stimulus	1.70E-08

GO:0009719	Response to endogenous stimulus	2.30E-08

GO:0050896	Response to stimulus	4.00E-07

GO:0006281	DNA repair	4.40E-05

GO:0042770	DNA damage response, signal transduction	5.90E-05

GO:0007049	Cell cycle	1.40E-03

GO:0006464	Protein modification process	1.60E-03

GO:0022402	Cell cycle process	2.70E-03

GO:0016071	mRNA metabolic process	1.20E-61

GO:0006397	mRNA processing	4.80E-61

GO:0008380	RNA splicing	1.20E-58

GO:0005681	Spliceosome	1.90E-38

GO:0006396	RNA processing	5.80E-34

GO:0030529	Ribonucleoprotein complex	1.90E-26

GO:0003723	RNA binding	2.00E-25

GO:0016070	RNA metabolic process	1.70E-06

GO:0000377	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	4.10E-06

GO:0000398	Nuclear mRNA splicing, via spliceosome	4.10E-06


Condition or therapy	No. (%)	BRS (ms/mmHg)	p value for interaction

Hypertension

Yes	68 (72)	8.5 ± 4.4	0.056

No	26 (28)	10.4 ± 4.6

Hyperlipidemia

Yes	83 (88)	8.8 ± 4.4	0.424

No	11 (12)	10.0 ± 5.8

Smoking

Yes	30 (32)	9.9 ± 4.5	0.177

No	64 (68)	8.5 ± 4.5

Sulfonylurea use

Yes	25 (27)	7.1 ± 3.2	0.015


Level of Confidence	Low	Medium 	High

Studies	Gessner et al. (1997-b)	Akaeda et al. (1998)	Gessner et al. (1997-a)

Prakash et al. (1971)	Bond and Medcoff (1958)	Knaack et al. (2016)

Rodrigue et al. (1990)	Garcia et al. (2004)	-

Sharifzadeh et al. (1991)	Garcia et al. (2005)	-

Tennant et al. (1955)	Gessner and Middaugh (1995)	-

Turnbull et al. (2013)	Langeland et al. (1984)	-

-	Popkiss et al. (1979)	-

Level of Confidence	Low	Medium

Studies	Gessner et al. (1997-b)	Akaeda et al. (1998)

Prakash et al. (1971)	Bond and Medcoff (1958)

Rodrigue et al. (1990)	Garcia et al. (2004)

Sharifzadeh et al. (1991)	Garcia et al. (2005)

Tennant et al. (1955)	Gessner and Middaugh (1995)

Turnbull et al. (2013)	Langeland et al. (1984)

-	Popkiss et al. (1979)

High

Gessner et al. (1997-a)

Knaack et al. (2016)

-

-

-

-

-


Source	Allograft	Time from transplant	Risk factors	Presentation	Diagnostic test	Treatment	Outcome

Schaeffer et al. [9]	Heart	2 months	Travel to southeastern US	Perforated colon	BAL examination	Thiabendazole × 15 daysIvermectin × 15 days	Death

El Masry and O'Donnell [10]	Heart	41 days	From Kentucky	Respiratory distress	Alveolar tissue onautopsy	None	Death

Mizuno et al. [11]	Heart/kidney	28 days	From Florida	Respiratory distress	Autopsy findings	None	Death

Roxby et al. [8]	Heart	2 months	Immigrantfrom Ethiopia	DyspneaAbdominal painNausea	Sputumexamination	Oralivermectin	Death

Brügemann et al. [12]	Heart	6 weeks	 	AbdominalpainAnorexiaNausea	Skin biopsy	Oral ivermectin × 15 daysAlbendazole oral × 10 days	Successfultreatment

Grover et al. [13]	Heart	4 weeks	From SoutheasternUS	Nauseavomiting	Duodenalbiopsy	Ivermectin	Death

Source	Allograft	Time from transplant	Risk factors	Presentation	Diagnostic test	Treatment	Outcome

Schaeffer et al. [9]	Heart	2 months	Travel to southeastern US	Perforated colon	BAL examination	Thiabendazole × 15 daysIvermectin × 15 days	Death

El Masry	He	41 d	From Kentu	Respir	Alveolar ti	None	D

Source	Allograft	Time from transplant	Risk factors	Presentation	Diagnostic test	Treatment	Outcome

 and O'Donnell [10]	art	ays	cky	atory distress	ssue onautopsy		eath

Mizuno et al. [11]	Heart/kidney	28 days	From Florida	Respiratory distress	Autopsy findings	None	Death

Roxby et al. [8]	Heart	2 months	Immigrantfrom Ethiopia	DyspneaAbdominal painNausea	Sputumexamination	Oralivermectin	Death

Brügemann et al. [12]	Heart	6 weeks		AbdominalpainAnorexiaNausea	Skin biopsy	Oral ivermectin × 15 daysAlbendazole oral × 10 days	Successfultreatment

Grover et al. [13]	Heart	4 weeks	From SoutheasternUS	Nauseavomiting	Duodenalbiopsy	Ivermectin	Death


Before	8 hours	24 hours	48 hours	5 days

23 ± 4	401 ± 27	383 ± 1	272 ± 9	130 ± 14


Item	First sensation threshold	Defecation urge threshold	Pain detection threshold

	Before Treatment	After Treatment	Difference	Before Treatment	After Treatment	Difference	Before Treatment	After Treatment	Difference


	Predicting from Overt Victimization	Predicting from Relational Victimization

	CBCL Externalizing	CBCL Internalizing	CBCL Externalizing	CBCL Internalizing

	∆R2	β	∆R2	β	∆R2	β	∆R2	β

Step 1	0.02		0.03		0.02		0.03

 	Age		−0.12		 0.18		−0.12		 0.18

Step 2	0.11		0.13		0.11		0.13

 	Child Fearful Bias		 0.21		 0.07		 0.21		 0.07

 	Parent Fearful Bias		−0.02		−0.10		−0.02		−0.10

 	Parent TAS DIF		 0.32 *		 0.36 **		 0.32 *		 0.36 **

Step 3	0.00		0.04		0.01		0.10 *

 	Perceived Impairment		 0.02		−0.22		−0.14		−0.37 *

Step 4	0.13 *		0.10 *		0.08		0.09

 	Child-reported Victimization		−0.09		−0.10		−0.01		−0.12

 	Parent-reported Victimization		0.40 **		 0.34 *		 0.31*		 0.35 *

	Predicting from Overt Victimization	Predicting from Relational Victimization

	CBCL Externalizing	CBCL Internalizing	CBCL Externalizing	CBCL Internalizing

	∆R2	β	∆R2	β	∆R2	β	∆R2

Step 1	0.02		0.03		0.02		0.03

	Age		−0.12		0.18		−0.12

Step 2	0.11		0.13		0.11		0.13

	Child Fearful Bias		0.21		0.07		0.21

	Parent Fearful Bias		−0.02		−0.10		−0.02

	Parent TAS DIF		0.32 *		0.36 **		0.32 *

Step 3	0.00		0.04		0.01		0.10 *

	Perceived Impairment		0.02		−0.22		−0.14

Step 4	0.13 *		0.10 *		0.08		0.09

	Child-reported Victimization		−0.09		−0.10		−0.01

	Parent-reported Victimization		0.40 **		0.34 *		0.31*

Predicting from Relational Victimization

CBCL Internalizing

β

0.18

0.07

−0.10

0.36 **

−0.37 *

−0.12

0.35 *


Symbola	Protein	Process	Alteration/disease

ADCYAP1R1	Adenylate cyclase-activating polypeptide receptor (PAC1)	Signaling pathway	Decreased second messenger

CASP3	Caspase 3	Protease	Apoptosis. Alzheimer’s disease

CCND1	G1/S-specific cyclin-D1	Interact with tumor suppressor protein Rb	Abnormal cell cycle G1/S transition

CNN1	Calporin (actin binding protein; fimbrin type)	Actin associated protein	Abnormal cohesion between parental centrioles

CREB1	cAMP-responsive element binding protein 1	Transcription factor	Altered development. ASD

CREM	cAMP-responsive element modulator	Transcription factor modulating CREB	Altered development. ASD

CTNNB1	β-catenin	Regulates the coordination of cell–cell adhesion and gene transcription	Altered asymmetric cell division, epithelial-to-mesenchymal transition. ASD

DYRK1A	Dual specificity tyrosine-phosphorylation- regulated kinase 1A	Nuclear signaling	Abnormal cell proliferation and may be involved in brain development. ASD

GNB1L	Guanine nucleotide-binding protein subunit β-like protein 1	Six WD40 repeat-containing protein	Abnormal cell cycle progression. Schizophrenia. ASD

FLT1	Vascular endothelial growth factor receptor 1	Protein kinase	Abnormal control of cell proliferation and differentiation. ASD

HIST1H1T	Histone H1t	Compaction of chromatin	Abnormal cell cycle and differentiation

HSD11B2	Corticosteroid 11-β-dehydrogenase isozyme 2	Hydrolysis of cortisol	Cortisol induction of growth-inhibition and/or pro-apoptosis embryonic development

MAPK1	Mitogen-activated protein kinase 1 (ERK2)	CREB1 phosphorylation signaling pathway	ASD

RGS3	Regulator of G-protein signaling 3	Ephrin-B signaling pathway	Early cell cycle exit and precocious differentiation


	Harmonic (n = 39)	Control (n = 40)	p-value

Total volume (ml)

 Univariate	2908 ± 2453	3898 ± 5791	0.382

 Multivariate-adjusted	2864 ± 715	3941 ± 706	0.293

Duration of draining (days)

 Univariate	23 ± 14	28 ± 15	0.195

 Multivariate-adjusted	24 ± 2	27 ± 2	0.290


KEGG pathway	p value	Number of DEGs found in the KEGG pathway	Ratio (%)

Pathways in cancer	2.1e-4	9	10.1

Cytokine-cytokine receptor interaction	2.1e-3	7	7.9

Basal cell carcinoma	2.9e-3	4	4.5

Retinol metabolism	3.3e-2	3	3.4

Hedgehog signaling pathway	3.5e-2	3	3.4


	Underlying Diagnosis	All Diagnoses

	Median	95% UI	Median

Adults	66.5	(65.9, 66.9)	75.9

Children	38.5	(37.0, 40.0)	64.0

Neonates	54.3	(52.2, 55.6)	58.9


Indices and Its Statements a	Total Sample n = 1107	Bottom Tertile n = 355/339	Middle Tertile n = 424/417	Upper Tertile n = 328/351	p-Value

Perceived health concerns

Health Concern Index b	6.9 (3.7)	3.0 (0.7)	6.6 (0.9)	11.6 (2.3)	<0.0001

I am concerned about gaining weight	3.1 (1.9)	1.0 (0.5)	3.6 (1.5)	4.6 (1.2)	<0.0001

I am concerned about the risk of high blood pressure	2.0 (1.4)	1.0 (0.3)	1.5 (0.7)	3.7 (1.3)	<0.0001

I am concerned about the risk of coronary heart disease	1.8 (1.3)	1.0 (0.3)	1.4 (0.8)	3.3 (1.4)	<0.0001

Perceived nutrition concerns

Nutrition Concern Index c	17.1 (6.6)	10.0 (1.7)	16.1 (1.9)	25.1 (4.2)	<0.0001

I am not concerned about getting a lot of salt in my food (re-coded)	3.7 (1.5)	3.4 (1.8)	3.8 (1.4)	3.7 (1.4)	0.1617

I am concerned about food additives in my food	2.6 (1.5)	1.4 (0.9)	2.7 (1.4)	3.5 (1.4)	<0.0001

I am concerned about getting a lot of sugar in my food	2.4 (1.6)	1.1 (0.7)	2.1 (1.2)	4.2 (1.2)	<0.0001

I am concerned about getting a lot of fat in my food	2.3 (1.6)	1.0 (0.4)	2.0 (1.3)	4.0 (1.3)	<0.0001

I am concerned about getting sufficient energy in my food	2.2 (1.5)	1.1 (0.5)	2.2 (1.3)	3.2 (1.5)	<0.0001

I am concerned about getting a lot of cholesterol in my food	2.1 (1.5)	1.0 (0.3)	1.7 (1.0)	3.6 (1.3)	<0.0001

I am concerned about getting many calories	1.9 (1.3)	1.0 (0.5)	1.7 (1.0)	2.9 (1.5)	<0.0001


Pathways	Genes	Descriptions	TPM	NOISeq	RT-qPCR

P. humilis	P. major	Log2FC	P-adj	Log2FC	P

Wnt	WNT5A	Protein Wnt-5a	48.06	148.61	−1.63	0.00E+00	–	–

PRICKLE1	Prickle-like protein 1	14.86	55.20	−1.89	2.75E-06	−0.17	1.10E-01

WIF1*†	Wnt inhibitory factor 1	7.28	57.05	−2.97	8.87E-06	−3.28	5.30E-06

NFATC3	Nuclear factor of activated T-cells, cytoplasmic 3	8.98	39.30	−2.13	9.47E-05	–	–

FZD4	Frizzled-4	16.67	89.95	−2.43	1.54E-04	–	–

LEF1	Lymphoid enhancer-binding factor 1	60.50	143.01	−1.24	1.77E-04	–	–

FRZB*	Secreted frizzled-related protein 3	71.32	150.58	−1.08	3.47E-04	−3.23	4.12E-05

DAAM2	Disheveled-associated activator of morphogenesis 2	2.48	15.04	−2.60	3.47E-04	–	–

CCND1	G1/S-specific cyclin-D1	24.35	69.13	−1.51	4.18E-04	–	–

PRKACB	cAMP-dependent protein kinase catalytic subunit beta	34.22	73.42	−1.10	4.97E-04	–	–

MAPK/FGF	FGF17	Fibroblast growth factor 17	45.91	0.38	6.91	0.00E + 00	0.50	4.18E-01

FGF13*†	Fibroblast growth factor 13	11.33	3.71	1.61	4.21E-04	7.37	1.23E-08

STK3	Serine/threonine-protein kinase 38	11.70	40.72	−1.80	4.64E-04	–	–

OCD	NFATC1*	Nuclear factor of activated T-cells, cytoplasmic 1	5.82	39.32	−2.76	1.60E-08	−3.21	2.16E-05

ITGB3*†	Integrin beta-3	0.76	6.43	−3.08	8.57E-05	−5.49	1.21E-06

Notch	HES5	Transcription factor HES-5	117.76	17.23	2.77	3.11E-04	0.22	6.83E-01

Calcium	CACNA1G	Voltage-dependent T-type calcium channel subunit alpha-1G	4.28	14.60	−1.77	5.79E-04	–	–

Pathways	Genes	Descriptions	TPM	NOISeq

P. humilis	P. major	Log2FC

Wnt	WNT5A	Protein Wnt-5a	48.06	148.61	−1.63

PRICKLE1	Prickle-like protein 1	14.86	55.20	−1.89

WIF1*†	Wnt inhibitory factor 1	7.28	57.05	−2.97

NFATC3	Nuclear factor of activated T-cells, cytoplasmic 3	8.98	39.30	−2.13

FZD4	Frizzled-4	16.67	89.95	−2.43

LEF1	Lymphoid enhancer-binding factor 1	60.50	143.01	−1.24

FRZB*	Secreted frizzled-related protein 3	71.32	150.58	−1.08

DAAM2	Disheveled-associated activator of morphogenesis 2	2.48	15.04	−2.60

CCND1	G1/S-specific cyclin-D1	24.35	69.13	−1.51

PRKACB	cAMP-dependent protein kinase catalytic subunit beta	34.22	73.42	−1.10

MAPK/FGF	FGF17	Fibroblast growth factor 17	45.91	0.38	6.91

FGF13*†	Fibroblast growth factor 13	11.33	3.71	1.61

STK3	Serine/threonine-protein kinase 38	11.70	40.72	−1.80

OCD	NFATC1*	Nuclear factor of activated T-cells, cytoplasmic 1	5.82	39.32	−2.76

ITGB3*†	Integrin beta-3	0.76	6.43	−3.08

Notch	HES5	Transcription factor HES-5	117.76	17.23	2.77

Calcium	CACNA1G	Voltage-dependent T-type calcium channel subunit alpha-1G	4.28	14.60	−1.77


Variable	Mean (range) or no. (%)

Total operative time (mins)	204.94 (180–300)

Docking time (mins)	9.06 (5–30)

Undocking time (mins)	5 (2–10)

Time for esophageal mobilization (mins)	104.08 (80–170)

Estimated blood loss (ml)	86.75 (50–200)

Lymphnode yield (no.)	18.36 (13–24)

ICU stay (days)	1 (1–3)

Hospital stay (days)	10.37 (10–13)

Nil by mouth (days)	9.40 (8–12)

Conversion (no.)	Nil

Margin positivity (no.)	2 (2.41)

Adjuvant chemotherapy (no.)	15 (18.07)

Complications (no.)

Dysphagia for solids	6 (7.23)

Pleural effusion	3 (3.61)

Aspiration pneumonia	1 (1.20)

Recurrent palsy	2 (2.41)

Anastomotic leak	3 (3.61)

Chyle leak	1 (1.20)

Port site metastasis	1 (1.20)

Surgical site infection	1 (1.20)

Sepsis	1 (1.20)


	Group A (n = 162)

Median (IQR) age, years	67 (61–72)

Median (IQR) PSA. ng/ml	8.10 (6.05–14.00)

Median IQR) f/t PSA-ratio,%	12 (9–17)

Median (IQR) prostate volume, ml	48 (35–60)

Suspicous DRE, n (%)	23 (14%)

No. of prior biopsies, n (%)

Primary biopsy	53 (33%)

1	59 (36%)

2	33 (20%)

≥3	17 (10%)

Localization of lesions with maximum PI-RADS on mpMRI, n (%)

Apex	72 (44%)

Midgland	43 (27%)

Base	47 (29%)

Anterior	45 (28%)

Median (IQR) no. of lesions per patient	1 (1–2)

Maximum diameter of lesions (mm)	14 (10–17)

Mean (SD) of cores taken per patient	13.7 (±1.6)

Mean (SD) TBs per patient	3.8 (±1.5)

Maximum mpMRI Score, n (%)a

PI-RADS 3	31 (19%)

PI-RADS 4	83 (51%)

PI-RADS 5	48 (30%)


Background characteristics		Frequency	Percentage

Sex	Female	298	73.2

Male	109	26.8

Age	18-24	75	18.4

25-34	178	43.8

35-44	87	21.4

45-54	36	8.8

55+	31	7.6

Marital status	Married	335	82.3

Single	48	11.8

Divorced	16	3.9

Widowed	8	2.0

Educational level	Illiterate	45	11.0

Grade 1-8	111	27.3

Grade 9.12	120	29.5

College and above	131	32.2

Religion	Protestant	268	65.8

Orthodox	88	21.6

Muslim	27	6.6

Catholic	24	5.9

Occupation	Gov’t employee	139	34.2

House wife	137	33.7

Merchant	59	7.6

Daily laborer	31	14.5

Others*	41	10.1

Marital status	Single	48	11.8

Divorced	16	3.9

Widowed	8	2.0

Educational level	Illiterate	45	11.0

Grade 1-8	111	27.3

Grade 9.12	120	29.5

College and above	131	32.2

Religion	Protestant	268	65.8

Orthodox	88	21.6

Muslim	27	6.6

Catholic	24	5.9

Occupation	Gov’t employee	139	34.2

House wife	137	33.7

Merchant	59	7.6

Daily laborer	31	14.5

Others*	41	10.1


	Pearson correlation	Secondary structure and interactions

		Target	Guide strand (intra-)	Guide strand (inter-)

Complete database	R	0.16	0.13	0.12

	Significance	<10−100	1.1 × 10−72	2.89 × 10−56

Dataset with duplex stability −35 ≤ ΔG ≤ −25 kcal/mol	R	–	0.045	–

	Significance	n.s.	0.0018	n.s.

Complete database

Dataset with duplex stability −35 ≤ ΔG ≤ −25 kcal/mol

Pearson correlation	Secondary structure and interactions

	Target	Guide strand (intra-)	Guide strand (inter-)

R	0.16	0.13	0.12

Significance	<10−100	1.1 × 10−72	2.89 × 10−56

R	–	0.045	–

Significance	n.s.	0.0018	n.s.


 Method 	 ASEF 	 nu-SVR 	 Deep CNN 	 Our method

 fps 	 66.7 	 0.82 	 8.3 	 10.5


	Odds ratio	95% CI

Age	1.04	1.01 to 1.07

Site of infection:

 Lung	1

 Abdomen	1.55	0.66 to 3.70

 Catheter	0.72	0.15 to 3.43

 Urinary tract	0.10	0.01 to 0.78

 Others	0.70	0.25 to 1.94

 Chronic alcohol abuse	3.20	0.90 to 11.42

 Acquisition in hospital	2.03	0.98 to 4.36

SOFA score day 1 (failure):

 Haematological	3.20	0.92 to 9.92

 Cardiovascular	2.78	1.37 to 5.64

 Neurological	2.39	0.76 to 7.48

 Renal	1.97	0.73 to 5.27

 Liver	1.67	0.46 to 6.08

 Lung	1.65	0.81 to 3.36

 ΔSOFA (3-1)	1.32	1.13 to 1.34

 APACHE II Score	1.02	0.97 to 1.08

 Pre ICU stay (days)	0.99	0.97 to 1.02

	Odds ratio	95% CI

APACHE II Score	1.02	0.97 to 1.08

Pre ICU stay (days)	0.99	0.97 to 1.02


 	€	Reference/data source

Visit practice nurse (€/minute)	0.85	Vektis, information centre on costs and quality of health care in the Netherlands, established by health care insurers.

Mean salary costs men (€/hour)	32.49	Manual Hakkaart-van Roijen et al. [18]

Mean salary costs women (€/hour)	25.94	Manual Hakkaart-van Roijen et al. [18]

Transportation costs per visit	3.44	1.1 km * €0.20/km (back and forth: €0.44) + €3 parking costs, based on the manual of Hakkaart-van Roijen et al. [18]

Weighing scale	45	Mean price according to the “Consumentenbond” (Dutch consumers organisation)

Pedometer	40	Mean price according to “thuisvergelijken.nl” (website with reviews on web shops)

Blood pressure device	120	Mean price according to “bloeddrukmetershop.nl”

Food diary and step diary	5	Price according to “weightwatchers.nl”

Medication	variable	2012 prices according to “medicijnkosten.nl”, site of the College of Health Insurances

	€

Visit practice nurse (€/minute)	0.85

Mean salary costs men (€/hour)	32.49

Mean salary costs women (€/hour)	25.94

Transportation costs per visit	3.44

Weighing scale	45

Pedometer	40

Blood pressure device	120

Food diary and step diary	5

Medication	variable

Reference/data source

Vektis, information centre on costs and quality of health care in the Netherlands, established by health care insurers.

Manual Hakkaart-van Roijen et al. [18]

Manual Hakkaart-van Roijen et al. [18]

1.1 km * €0.20/km (back and forth: €0.44) + €3 parking costs, based on the manual of Hakkaart-van Roijen et al. [18]

Mean price according to the “Consumentenbond” (Dutch consumers organisation)

Mean price according to “thuisvergelijken.nl” (website with reviews on web shops)

Mean price according to “bloeddrukmetershop.nl”

Price according to “weightwatchers.nl”

2012 prices according to “medicijnkosten.nl”, site of the College of Health Insurances


Characteristics	Patientsn = 85

Age	66 (range 43-87)

Hypertension	34 (39%)

Hormone replacement therapy	21 (24%)

Obesity (BMI ≥ 30)	19 (22.3%)

Histology:

 Endometrioid adenocarcinoma	73 (86%)

 Adenosquamous adenocarcinoma	1 (1%)

 Serous papillary adenocarcinoma	5 (6%)

 Clear cell adenocarcinoma	5 (6%)

 Carcinosarcoma	1 (1%)

Preoperative histological grade on biopsy

 1	41 (48.2%)

 2	22 (25.8%)

 3	11 (12.9%)

 NP	11 (12.9%)

Characteristics	Patientsn = 85

Carcinosarcoma	1 (1%)

Preoperative histological grade on biopsy

1	41 (48.2%)

2	22 (25.8%)

3	11 (12.9%)

NP	11 (12.9%)


Model – Variables	Odds Ratios for eGFR < 75(95% Confidence Interval)n = 51 events	P interaction (APOL1x SES measure)	Odds Ratios for Elevated ACR(95% Confidence Interval) n = 21 events	P interaction (APOL1x SES measure)

	High-risk versus Low-riskAPOL1variants	Low SES versus Higher SES Group		High-risk versus Low-riskAPOL1variants	Low SES versus Higher SES Group

Additive Models

APOL1, Education	1.60 (1.00, 2.57)	1.95 (1.50, 2.54)	0.4	3.89 (2.28, 6.63)	1.68 (0.34, 8.23)	0.823

APOL1, Employment	2.06 (1.53, 2.78)	4.64 (3.40, 6.33)	0.017*	3.12 (1.73, 5.63)	1.32 (0.83, 2.08)	0.894

APOL1, Health Insurance	1.92 (1.27, 2.90)	1.00 (0.53, 1.89)	0.662	3.04 (1.65, 5.60)	0.56 (0.14, 2.28)	**could not be determined

APOL1, Regular Health Care Source	1.91 (1.15, 3.17)	0.54 (0.31, 0.94)	0.871	3.09 (1.56, 6.13)	0.64 (0.14, 2.86)	**could not be determined

Model – Variables	Odds Ratios for eGFR < 75(95% Confidence Interval)n = 51 events	P interaction (APOL1x SES measure)	Odds Ratios for Elevated ACR(95% Confidence Interval) n = 21 events	P interaction (APOL1x SES measure)

	High-risk versus Low-riskAPOL1variants	Low SES versus Higher SES Group		High-risk versus Low-riskAPOL1variants	Low SES versus Higher SES Group

APOL1, Employment	2.06 (1.53, 2.78)	4.64 (3.40, 6.33)	0.017*	3.12 (1.73, 5.63)	1.32 (0.83, 2.08)	0.894

APOL1, Health Insurance	1.92 (1.27, 2.90)	1.00 (0.53, 1.89)	0.662	3.04 (1.65, 5.60)	0.56 (0.14, 2.28)	**could not be determined

APOL1, Regular Health Care Source	1.91 (1.15, 3.17)	0.54 (0.31, 0.94)	0.871	3.09 (1.56, 6.13)	0.64 (0.14, 2.86)	**could not be determined


Exposure (exposure contrast)	n	ABI < 0.9		ABI > 1.3

NO2 (25 μg/m3)

Model 1a	2,698	0.65	(0.28, 1.52)	1.91	(1.09, 3.33)

Model 2b (possible intermediates)	2,600	0.72	(0.29, 1.75)	1.98	(1.09, 3.6)

Traffic load in a 100 m bufferc (7,200,000 veh-m/day)

Model 1	2,698	0.92	(0.37, 2.3)	1.89	(1.1, 3.26)

Model 2 (possible intermediates)	2,600	1.02	(0.4, 2.61)	1.89	(1.07, 3.34)

Traffic intensity in nearest street (15,000 veh/day)

Model 1	2,698	0.47	(0.16, 1.41)	1.6	(1.08, 2.38)

Model 2 (possible intermediates)	2,600	0.48	(0.16, 1.46)	1.7	(1.13, 2.57)

veh, vehicle. aEstimates adjusted by model 1: sex, age,sex–age interaction, smoking status, education, and marital status.bEstimates adjusted by model 2: sex, age, sex–age interaction, smokingstatus, education, marital status, BMI, HDL, waist circumference,systolic and diastolic blood pressure, weekly energy expenditure inphysical activity during leisure time (tertiles), adherence toMediterranean diet, plausibility of reported diet, medication treatment,and percentage of persons with low education at the census-tract level.cModels for traffic load were additionally adjusted for occupationalstatus.


Section	Award 1 point if

Selection bias (3 pts.)

 Goal and inclusion	Goal of the study is stated and study explicitly states the inclusion criteria

 Selection of patients	Selective recruitment of patients can be ruled out

 Patient characteristics	Study reports the age range and mean age and states the distribution of men and women

Outcome bias (3 pts.)

 Definition of subsidence	Definition of subsidence, classification, and radiological tools to measure subsidence were stated

 Clinical outcome	Clinical outcome was systematically evaluated in correlation to subsidence

 Preoperative status	Preoperative status was stated for comparison with postoperative status

Follow-up bias (2 pts.)

 Follow-up period	Follow-up range, period, and mean were given:

 • If yes and prospective study: 2 points

 • If yes and retrospective study: 1 point

 • If no, but loss to follow-up < 20%: 1 point

 • If too little information: 0 points

Other bias (3 pts.)

 Clinical evaluation	Evaluation was done independently from treating physician

 Radiologic evaluation	Evaluation was done by an independent party, blinded to clinical results

 Independence	Independence is explicitly stated, conflict of interest can be ruled out

Total (11 points)


	Students, N = 65	Mothers, N = 63

Pre	Post	Pre	Post

Cervical cancer is caused by HPV infection?	46%	100%	86%	97%

Cervical cancer is genetic?	51%	63%	71%	81%

All HPV infections lead to cervical cancer?	75%	49%	89%	76%

Cervical cancer is decreasing in recent years?	83%	92%	100%	98%

Cervical cancer is preventable?	72%	97%	70%	78%

Cervical cancer is asymptomatic usually in early stage?	65%	97%	98%	98%

Early detection of cervical cancer might save one’s life?	85%	92%	95%	97%

HPV is sexually transmitted?	NA	NA	91%	97%

If vaccinated, you don’t need to be screened?	NA	NA	98%	97%

Screening test should be done regularly?	NA	NA	92%	95%

HPV vaccination can prevent cervical cancer	NA	NA	95%	95%

Safe sex (steady partner, use of condoms) can prevent cervical cancer	NA	NA	75%	89%

Pap test can prevent cervical cancer	NA	NA	94%	95%

Healthy lifestyle (ie., regular exercise, disciplined lifestyle, healthy diet) can prevent cervical cancer	NA	NA	11%	11%


 	AS	Rett	MWS	FOXG1	KS	PMS	PHS	CS	CDKL5	MEF2C 	ARTX

Microcephaly	+	+	+	+	+	 	+	+	+	+	+

Seizure	+	+	+	+	+	 	+	+	+	+

Speech impairment	+	+	+	+	+	+	+	+	 	+	+

Ataxia	+	+	 	 	 	 	+	+	 	+

Stereotypical hand movements	+/−	+	 	+	 	 	+	 	+	+

Tremulous/jerky limb movements 	+

Happy predisposition	+	+	+	 	 	 	+	 	 	 	+

Abnormal MRI	 	 	+	+	 	+	+	+

Hyperventilation/apnea episode	 	+	 	 	 	 	+

Sleep disturbances	+	+	 	+	+	+

Hirschsprung disease	 	 	+

Lack of purposeful hand use	 	+

Prominent jaw/chin	+	 	+

Wide mouth 	+	 	+	 	 	 	+

Upturned ear lobes	 	 	+

Genital anomalies	 	 	 	 	+	 	 	 	 	 	+

Congenital heart disease 	 	 	+	 	+	 	 	 	 	 	+

Developmental regression 	 	+	 	 	 	+	 	+

Others 	 	In female only	 	 	 	Mild overgrowth 	Persistent finger pad Constipation	In male only 	 	 	In male only HbH in blood smear

	AS	Rett	MWS	FOXG1	KS	PMS	PHS	CS	CDKL5

Microcephaly	+	+	+	+	+		+	+	+

Seizure	+	+	+	+	+		+	+	+

Speech impairment	+	+	+	+	+	+	+	+

Ataxia	+	+					+	+

Stereotypical hand movements	+/−	+		+			+		+

Tremulous/jerky limb movements	+

Happy predisposition	+	+	+				+

Abnormal MRI			+	+		+	+	+

Hyperventilation/apnea episode		+					+

Sleep disturbances	+	+		+	+	+

Hirschsprung disease			+

Lack of purposeful hand use		+

Prominent jaw/chin	+		+

Wide mouth	+		+				+

Upturned ear lobes			+

Genital anomalies					+

Congenital heart disease			+		+

Developmental regression		+				+		+

Others		In female only				Mild overgrowth	Persistent finger pad Constipation	In male only

MEF2C	ARTX

+	+

+

+	+

+

+

	+

	+

	+

	In male only HbH in blood smear


Variable	Response options	Total motorcycle riders	Non-helmet user

Number	%	Number	%

Helmet use experiences and attitudes

Been in accident before 	No	12,649	66.6	5,479	43.5

Yes	6,349	33.4	2,890	45.7

Rider status when in accident 	Rider	4,557	75.7	2,146	47.2

Passenger	1,370	22.8	601	44.1

Pedestrian	93	1.5	37	39.8

Have you ever used a helmet before	No	7,600	40.2	5,925	52.6

Yes	11,290	59.8	2,395	31.7

Perceived danger of not using a helmet	No	4,720	25.0	2,008	42.7

Yes	14,175	75.0	6,316	44.7

Aware of danger of not using a helmet 	Low	840	4.4	425	50.7

Moderate	7,525	39.8	3,328	44.4

High	10,544	55.8	4,580	43.6

Perceived risk about being caught by the police because of not using a helmet	High risk	7,788	41.3	3,602	46.4

Moderate risk	7,411	39.3	3,271	44.3

Low risk	2,078	11.0	855	41.3

No risk	1,595	8.5	584	36.7

Ever been caught by police because of not using a helmet	No	8,918	52.8	3,839	38.6

Yes	9,983	47.2	4,483	50.4

Exposure to road safety awareness (RSA) campaign

Heard advertising campaign on RSA 	No	3,066	16.1	1,428	46.9

Yes	15,926	83.9	6,938	43.7

RTI campaign on radio or TV 	Never	2,476	13.2	1,198	48.5

Not often	10,253	54.5	4,391	43.0

Frequently	5,493	29.2	2,409	44.0

Not sure	587	3.1	272	46.4

Talking to others about RSA in the media 	Never	7,729	40.8	3,789	49.2

Ever	7,600	40.1	3,031	40.0

Not sure	3,620	19.1	1,533	42.6

How feel about RSA media 	Not like	1,119	5.9	560	50.0

Like a little bit	11,676	61.7	5,148	44.3

Like very 	5,173	27.3	2,205	42.7

much	955	5.0	433	45.4

Not sure

Follows the TV news report on RSA statistics 	Never	2,614	13.8	1,256	48.2

Not often	9,841	52.0	4,415	45.0

Frequently	5,552	29.3	2,244	40.6

Not sure	912	4.8	436	48.2

Variable	Response options	Total motorcycle riders	Non-helmet user

Number	%	Number	%

How feel about RSA media	Not like	1,119	5.9	560	50.0

Like a little bit	11,676	61.7	5,148	44.3

Like very	5,173	27.3	2,205	42.7

much	955	5.0	433	45.4

Not sure

Follows the TV news report on RSA statistics	Never	2,614	13.8	1,256	48.2

Not often	9,841	52.0	4,415	45.0

Frequently	5,552	29.3	2,244	40.6

Not sure	912	4.8	436	48.2


	Conventional CPB	Mini-CPB	P value

Patients (no.)	22		22

Women/men (no.)	4/18		2/20		0.66

Age (years)	68	(63–71)	69	(66–74)	0.57

Body mass index	28.5	(25.3–32)	26.5	(25–31.3)	0.38

Acetylsalicylic acid (no.)	21		21

Beta blockers (no.)	21		20

ACE inhibitors (no.)	16		18		0.72

Statins (no.)	21		20

Diabetes mellitus (no.)	4		6		0.72

COPD (no.)	3		4

Prior myocardial infarction (no.)	12		9		0.37

Leukocytes (cells ×109/L)	7.5	(6.8–8.5)	7.1	(6.3–8.8)	0.8

Ejection fraction (%)	64.5	(51.3–69.8)	60	(48.5–69.5)	0.35

	Conventional CPB

Patients (no.)	22

Women/men (no.)	4/18

Age (years)	68	(63–71)

Body mass index	28.5	(25.3–32)

Acetylsalicylic acid (no.)	21

Beta blockers (no.)	21

ACE inhibitors (no.)	16

Statins (no.)	21

Diabetes mellitus (no.)	4

COPD (no.)	3

Prior myocardial infarction (no.)	12

Leukocytes (cells ×109/L)	7.5	(6.8–8.5)

Ejection fraction (%)	64.5	(51.3–69.8)


Cluster ID	#sequences	#non-redundant sequences	Description

CAM_CL_2057	20,508	24	Reverse transcriptase (HIV)

CAM_CL_1132	18,882	1,406	Cytochrome c oxidase subunit I

CAM_CL_2568	15,405	6,091	ABC transporter

CAM_CL_4367	15,228	771	Cytochrome b

CAM_CL_49	14,751	7,389	Short-chain dehydrogenase

CAM_CL_3510	13,255	5,173	Immunoglobulin

CAM_CL_2630	13,140	3,297	Envelope glycoprotein

CAM_CL_160	13,054	3,897	Kinases

CAM_CL_4556	12,403	6,345	Response regulator

CAM_CL_481	12,078	5,477	Transcription regulator


Cell line	dCK activity	dGK activity

48 h	72 h	Quiescence	48 h	72 h	Quiescence

P3	16.5 ± 0.3	11.4 ± 0.2	8.0 ± 1.2	0.04 ± 0.01	0.16 ± 0.01	≤0.01


Dependant Variable	Worse-than-Dead	Euthanasia

Coefficient	Standard Error	Coefficient	Standard Error

Third Level Education	−0.155	(0.167)	−0.077	(0.255)

Age Group (Base: 18–35)

 36–45	0.304	(0.207)	0.328	(0.32)

 46–60	0.471*	(0.228)	0.318	(0.42)

 61+	1.168***	(0.274)	0.585	(0.489)

Male	−0.298	(0.17)	−0.113	(0.251)

Married/Living as Married	−0.158	(0.204)	−0.07	(0.303)

Dependants Under 18 (Y/N)	−0.098	(0.208)	0.412	(0.359)

Visual Analogue Scale	0.004	(0.006)	−0.012	(0.008)

Experienced a serious illness	−0.287	(0.264)	−0.765*	(0.3)

In favour of Legalisation of Euthanasia (see scenario in Fig. 1)	1.003*	(0.394)	–	–

Religiosity (Base: A few times a year or less)

 Monthly	–	–	−0.454	(0.318)

 Weekly	–	–	−1.369***	(0.328)

Mobility (Base: No Problems)

 Slight problems	0.194	(0.114)	–	–

 Moderate problems	0.326**	(0.109)	–	–

 Severe problems	0.476***	(0.12)	–	–

 Unable	0.419***	(0.112)	–	–

Self-care (Base: No Problems)

 Slight problems	0.263*	(0.128)	–	–

 Moderate problems	0.34*	(0.131)	–	–

 Severe problems	0.528***	(0.143)	–	–

 Unable	0.444***	(0.102)	–	–

Usual Activities (Base: No Problems)

 Slight problems	0.304*	(0.134)	–	–

 Moderate problems	0.477**	(0.156)	–	–

 Severe problems	0.443***	(0.118)	–	–

 Unable	0.335***	(0.091)	–	–

Paid/Discomfort (Base: No Problems)

 Slight problems	0.253*	(0.116)	–	–

 Moderate problems	0.182	(0.116)	–	–

 Severe problems	0.614***	(0.111)	–	–

 Extreme problems	0.852***	(0.138)	–	–

Anxiety/Depression (Base: No Problems)

 Slight problems	0.221	(0.128)	–	–

 Moderate problems	0.313*	(0.14)	–	–

 Severe problems	0.867***	(0.159)	–	–

 Extreme problems	0.858***	(0.133)	–	–

Constant	−3.331***	(0.626)	2.05**	(0.748)

Rhoa			−0.801*	(0.402)

Number of observationsa				1600

Number of clustersa				160

Dependant Variable	Worse-than-Dead	Euthanasia

Coefficient	Standard Error	Coefficient	Standard Error

Age Group (Base: 18–35)

36–45	0.304	(0.207)	0.328	(0.32)

46–60	0.471*	(0.228)	0.318	(0.42)

61+	1.168***	(0.274)	0.585	(0.489)

Male	−0.298	(0.17)	−0.113	(0.251)

Married/Living as Married	−0.158	(0.204)	−0.07	(0.303)

Dependants Under 18 (Y/N)	−0.098	(0.208)	0.412	(0.359)

Visual Analogue Scale	0.004	(0.006)	−0.012	(0.008)

Experienced a serious illness	−0.287	(0.264)	−0.765*	(0.3)

In favour of Legalisation of Euthanasia (see scenario in Fig. 1)	1.003*	(0.394)	–	–

Religiosity (Base: A few times a year or less)

Monthly	–	–	−0.454	(0.318)

Weekly	–	–	−1.369***	(0.328)

Mobility (Base: No Problems)

Slight problems	0.194	(0.114)	–	–

Moderate problems	0.326**	(0.109)	–	–

Severe problems	0.476***	(0.12)	–	–

Unable	0.419***	(0.112)	–	–

Self-care (Base: No Problems)

Slight problems	0.263*	(0.128)	–	–

Moderate problems	0.34*	(0.131)	–	–

Severe problems	0.528***	(0.143)	–	–

Unable	0.444***	(0.102)	–	–

Usual Activities (Base: No Problems)

Slight problems	0.304*	(0.134)	–	–

Moderate problems	0.477**	(0.156)	–	–

Severe problems	0.443***	(0.118)	–	–

Unable	0.335***	(0.091)	–	–

Paid/Discomfort (Base: No Problems)

Slight problems	0.253*	(0.116)	–	–

Moderate problems	0.182	(0.116)	–	–

Severe problems	0.614***	(0.111)	–	–

Extreme problems	0.852***	(0.138)	–	–

Anxiety/Depression (Base: No Problems)

Slight problems	0.221	(0.128)	–	–

Moderate problems	0.313*	(0.14)	–	–

Severe problems	0.867***	(0.159)	–	–

Extreme problems	0.858***	(0.133)	–	–

Constant	−3.331***	(0.626)	2.05**	(0.748)

Rhoa			−0.801*	(0.402)

Number of observationsa				1600

Number of clustersa				160


Clinical trial	Number of patients	Experimental arm	Control arm	Overall/annual fracture incidence	References

ATAC	9366	Anastrozole	Tamoxifen	Overall: 11 vs. 7.7%Annual: 2.93 vs. 1.90%	[57, 58]

IBIS II bone sub-study	1410	Anastrozole	Placebo	Annual: 1.37 vs. 1.26%	[100]

BIG 1.98	4895	Letrozole	Tamoxifen	Overall: 9.3 vs. 6.5%Annual: 2.71 vs. 1.872%	[59]

MA-17	5187	Letrozole	Placebo	Overall: 3.6 vs. 2.9%	[60]

IES	4274	Exemestane	Tamoxifen	Overall: 7 vs. 5%Annual: 2.01 vs. 1.60%	[61]

ABCSG-18	3420	AI + denosumab	AI + placebo	Overall: 5 vs. 9.6%	[107]


Instrument	Baseline	Follow-up

SCAN [38]	x

PANSS [41]	x	x

Insight Scale [39]	x	x

Early Signs Scale [40]	x	x

DUP [42]		x

PAS [44]		x

Encounter Form [45]		x


How detected	% of total

Test recommended by general practitioners	27.1

Sexual partner tracing	21.7

Voluntary testing	12.1

Blood donors	9.7

HIV test done in hospitals	8.9

Persons with other sexually transmitted infections	8.3

Pregnant women	1.6

Other	10.6

Total	100% (n = 4276)

How detected	% of total

Voluntary testing	12.1

Blood donors	9.7

HIV test done in hospitals	8.9

Persons with other sexually transmitted infections	8.3

Pregnant women	1.6

Other	10.6

Total	100% (n = 4276)


Gender	NO. examined	NO. positive	Prevalence (%)

Male	52	9	17.31

Female	140	11	7.86

Total	192	20	10.42


Objective	Activity

Training To understand the nutrient content and ingredients in processed and fast food and make a homemade burger	‘Ready, steady, cook’. Demonstration used a fast food burger recipe to illustrate poor quality of ‘fast food’. Peer supporters then made their own burger for lunch (meat or vegetarian) to demonstrate the difference in ingredients

 To taste different fruit and vegetables	‘Taste trial’. Fresh fruit and vegetables were plated. Peer supporter volunteers were blindfolded and asked to guess the name of the fruit or vegetable they had tried, and describe the taste and texture

 To emphasize the range of physical activity options	‘A-Z’. Peer supporters were asked to think of a physical activity beginning with each letter of the alphabet

 To understand what sedentary behaviour is and its health implications	‘Before and after’ role plays. Sedentary behaviour (before) changed to active behaviour (after), e.g. taking the lift changed to walking the stairs

 To consider barriers to physical activity and think of solutions	‘Barrier wall’. A wall of cardboard box ‘bricks’ was constructed. Peer supporters were asked to think of barriers to physical activity, which were written onto the bricks. Peer supporters who thought of solutions to barriers were allowed to remove the relevant brick until the wall was demolished

 To develop communication skills for their role	‘Role play’. Peer supporters improvised conversations with their peers based on key messages about physical activity or healthy eating

 To use goal setting to change health behaviour	‘Goal setting’. Peer supporters set themselves a small challenge in relation to physical activity or healthy eating. This was revisited at the follow-up sessions

Support ‘follow-up sessions’

 To understand the salt, sugar, fat and fibre content of various foods	A game of top trump cards. Cards display different food products. The winning card has the ‘healthiest’ level of a selected ingredient, e.g. salt, sugar, fat or fibre

 To remind peer supporters of the importance of breakfast	A morning session with a discussion about how to make healthy choices at breakfast during which volunteers serve breakfast to their peers

 To evaluate health promotion posters	Peer supporters complete jigsaws of current health promotion posters relating to physical activity and healthy eating, and discuss which they consider would have the greatest impact on their peers

 To experience physical activity	Physical activity sessions including skipping, circus skills and Frisbee


	RA	AS	HC	P

HAT (ng/h/mg)

(mean ± SEM)	126.8 ± 16.4	68.2 ± 8.1	111.3 ± 15.5	RA vs HC:NS*

				AS vs HC: p=0.05*

HDAC (pmol/min/mg)

(mean ± SEM)	3915.9 ±790.3	1984.6 ± 249.0	4778.9 ± 752.3	RA vs HC:NS*

				AS vs HC: p=0.01*

Ratio HDAC/HAT

(mean ± SEM)	49.1 ± 16.7	35.6 ± 6.9	65.4 ± 16.7	NS*

HAT + TSA (ng/h/mg)

(mean ± SEM)	153.2 ± 30.3	81.2 ± 9.9	112.6 ± 21	HAT vs HAT + TSA**:HC:NS

				RA: NS AS: NS

HAT + Sirt (ng/h/mg)

(mean ± SEM)	113.1 ± 14.0	71.9 ± 6.2	107.9 ± 15.9	HAT vs HAT+ Sirt** HC:NS

				RA: p = 0.01

				AS: NS

HDAC + TSA (pmol/min/mg)

(mean ± SEM)	2457.1± 316.4	2134.2 ± 426.3	3450.6 ± 709.1	HDAC vs HDAC + TSA** HC:NS

				RA: NS AS: NS

HDAC + Sirt (pmol/min/mg)

(mean ± SEM)	2440.6 ± 446.4	1975.4 ± 313.2	2341.6 ± 242.7	HDAC vs HDAC + Sirt**

				HC: p = 0.07

				RA: NS AS: NS

	RA	AS	HC	P

(mean ± SEM)	3915.9 ±790.3	1984.6 ± 249.0	4778.9 ± 752.3	RA vs HC:NS*

				AS vs HC: p=0.01*

Ratio HDAC/HAT

(mean ± SEM)	49.1 ± 16.7	35.6 ± 6.9	65.4 ± 16.7	NS*

HAT + TSA (ng/h/mg)

(mean ± SEM)	153.2 ± 30.3	81.2 ± 9.9	112.6 ± 21	HAT vs HAT + TSA**:HC:NS

				RA: NS AS: NS

HAT + Sirt (ng/h/mg)

(mean ± SEM)	113.1 ± 14.0	71.9 ± 6.2	107.9 ± 15.9	HAT vs HAT+ Sirt** HC:NS

				RA: p = 0.01

				AS: NS

HDAC + TSA (pmol/min/mg)

(mean ± SEM)	2457.1± 316.4	2134.2 ± 426.3	3450.6 ± 709.1	HDAC vs HDAC + TSA** HC:NS

				RA: NS AS: NS

HDAC + Sirt (pmol/min/mg)

(mean ± SEM)	2440.6 ± 446.4	1975.4 ± 313.2	2341.6 ± 242.7	HDAC vs HDAC + Sirt**

				HC: p = 0.07

				RA: NS AS: NS


Path	Mediator	Coeff.	SE	t	p

Interaction variable to mediators	Identity Compatibility	0.12	0.04	2.93	0.00

	Identity Expression	0.08	0.04	2.29	0.02

Mediators to outcome variable	Identity Compatibility	0.24	0.12	1.96	0.05

	Identity Expression	0.26	0.10	2.49	0.01

Path	Mediator

Interaction variable to mediators	Identity Compatibility

	Identity Expression

Mediators to outcome variable	Identity Compatibility

	Identity Expression


Variable	B	SE	Wald	P value	Odds ratio	95 % confidence interval for EXP(B)

Lower limit	Upper limit

Percentage of monocytes expressing PD-L1	1.943	0.745	6.811	0.009	6.981	1.622	30.041

Lymphocytes	0.088	0.794	0.012	0.912	1.092	0.230	5.173

SOFA sco		0		0.024		1.22	18.1


Psychological and other health measures (Denominatora)	n = 609

HADs anxiety subscale (607)

 Normal	316 (52.1)

 Mild/possible case	120 (19.8)

 Probable/moderate/severe case	171 (28.2)

HADs depression subscale (609)

 Normal	392 (64.4)

 Mild/possible case	119 (19.5)

 Probable/moderate/severe case	98 (16.1)

Pain self-efficacy score (593), mean (SD)	34.1 (14.6)

Illness perceptions questionnaire-short form (IPQ-R)

 Timeline-‘back/leg pain will last for a long time (agree or strongly agree) (609)	345 (56.7)

 Personal control-‘what I do can determine whether back/leg pain gets better (agree or strongly agree) (605)	367 (60.7)

 Identity score (0–7) (584), mean (SD)	5.9 (1.3)

General Health (608)

 Excellent/very good	146 (24.0)

 Good	241 (39.5)

 Fair	172 (28.3)

 Poor	50 (8.2)

Co-morbiditiesb(609)

 None	371 (60.9)

 One other health problem	158 (25.9)

 Two or more other health problems	80 (13.1)

EQ—5D—3L summary index (590)	0.44 (0.32)

Psychological and other health measures (Denominatora)	n = 609

One other health problem	158 (25.9)

Two or more other health problems	80 (13.1)

EQ—5D—3L summary index (590)	0.44 (0.32)


	The Akershus Birth Cohort Study	All woman who gave birth in Norway in 2010

Mean maternal age	31.3 years	30.2 years

First time mothers	48.9 %	42.6 %

Smoking during pregnancy	6.6 %	7.2 %

Single women	1.1 %	9.1 %

Elective caesarean section	5.0 %	6.5 %


	Vitamin D	Vitamin D	Dyslipidemia	Overweight

	deficiency	Insufficiency

	Adjusted	P	Adjusted	P	Adjusted	P	Adjusted	P

	OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)

NADSYN1rs12785878 G > T

TT - GT	1		1		1		1

GG	1.72 (0.69 - 4.24)	0.54	1.80 (1.12 - 2.87)	0.01	1.72 (1.04 - 2.86)	0.03	1.02 (0.62 - 1.69)	0.93


Patellar dislocation N = 51	Group ANonoperatively treated patientsn = 33	Group BPatients treated operatively during acute phasen = 7	Group CPatients treated operatively due to recurrence n = 11

Girls : boys	16 : 17	4 : 3	9 : 2

Age at injury (years)a	13.5 ± 1.3	12.6 ± 2.3	13.3 ± 1.5

Follow-up time (years)a	7.7 ± 1.5	7.0 ± 1.4	7.3 ± 1.5

Trochlear dysplasia	67% (22 of 33)	83% (5 of 6)	64% (7 of 11)

Patella alta	33% (11 of 33)	33% (2 of 6)	38% (3 of 8)

Subjective knee functiona

 KOOS subscales at follow-upb

(i) Pain (M = 92, F = 92)	90 ± 14	92 ± 8	86 ± 9

(ii) Symptoms (M = 87, F = 89)	82 ± 14	82 ± 11	78 ± 12

(iii) Function in daily living (M = 94, F = 95)	94 ± 12	97 ± 4	93 ± 6

(iv) Sports and recreation (M = 85, F = 86)	77 ± 24	79 ± 15	66 ± 17

(v) Quality of life (M = 85, F = 84)	69 ± 20	76 ± 19	60 ± 14

 Kujala score at follow-upc	84 ± 10	84 ± 7	75 ± 15

Objective knee functiona

 Peak torque/body weight

(i) Extension (90 degr/s)	187.2 ± 59.5	195.6 ± 57.4	157.9 ± 63.2

 	M: 220 ± 43	M: 242 ± 50	M: 231 ± 30

 	F: 152 ± 56	F: 161 ± 34	F: 142 ± 57

(ii) Flexion (90 degr/s)	106.3 ± 34.4	103.6 ± 31.7	113.8 ± 57.6

 	M: 128 ± 26	M: 124 ± 36	M: 208 ± 77

 	F: 83 ± 27	F: 88 ± 20	F: 93 ± 26

(iii) H/Q ratioe	0.58 ± 0.16	0.54 ± 0.12	1.03 ± 1.30

 LSI, peak torque in extensionf	86 ± 17%	89 ± 15%	81 ± 32%

 30 s mini squat test injured sideg	35 ± 15	36 ± 18	34 ± 13

 LSI, 30 s mini-squat testf	93 ± 21%	97 ± 8%	99 ± 32%

Redislocation after latest treatmenth	67% (22 of 33) 	43% (3 of 7)	18% (2 of 11)

Patellar dislocation N = 51	Group ANonoperatively treated patientsn = 33	Group BPatients treated operatively during acute phasen = 7

Girls : boys	16 : 17	4 : 3

Age at injury (years)a	13.5 ± 1.3	12.6 ± 2.3

Follow-up time (years)a	7.7 ± 1.5	7.0 ± 1.4

Trochlear dysplasia	67% (22 of 33)	83% (5 of 6)

Patella alta	33% (11 of 33)	33% (2 of 6)

Subjective knee functiona

KOOS subscales at follow-upb

(i) Pain (M = 92, F = 92)	90 ± 14	92 ± 8

(ii) Symptoms (M = 87, F = 89)	82 ± 14	82 ± 11

(iii) Function in daily living (M = 94, F = 95)	94 ± 12	97 ± 4

(iv) Sports and recreation (M = 85, F = 86)	77 ± 24	79 ± 15

(v) Quality of life (M = 85, F = 84)	69 ± 20	76 ± 19

Kujala score at follow-upc	84 ± 10	84 ± 7

Objective knee functiona

Peak torque/body weight

(i) Extension (90 degr/s)	187.2 ± 59.5	195.6 ± 57.4

	M: 220 ± 43	M: 242 ± 50

	F: 152 ± 56	F: 161 ± 34

(ii) Flexion (90 degr/s)	106.3 ± 34.4	103.6 ± 31.7

	M: 128 ± 26	M: 124 ± 36

	F: 83 ± 27	F: 88 ± 20

(iii) H/Q ratioe	0.58 ± 0.16	0.54 ± 0.12

LSI, peak torque in extensionf	86 ± 17%	89 ± 15%

30 s mini squat test injured sideg	35 ± 15	36 ± 18

LSI, 30 s mini-squat testf	93 ± 21%	97 ± 8%

Redislocation after latest treatmenth	67% (22 of 33)	43% (3 of 7)


	Aspira-aA	Tecnis ZCB00	p value

UDVA (logMAR)	0.14 ± 0.13	0.12 ± 0.15	0.25

CDVA (logMAR)	0.07 ± 0.09	0.04 ± 0.09	0.22

Sphere ∆ (D)	−0.22 ± 0.67	−0.50 ± 0.52	0.29

Depth of focus (D)	0.61 ± 0.33	0.65 ± 0.29	0.74

Corneal asphericity with a pupil size of 4 mm	0.19 ± 0.24	0.26 ± 0.16	0.19


	Number of persons	Mean age (range) in years	Males/females	Smokers (non-/NA/current /ex)a	Steroid treatment (no/NA/yes)a	Non-steroidal anti-inflammatory drug (no/NA/yes)a	Mean duration of symptoms (range) in monthsb

Group I	6	71 (65–78)	3/3	4/1/0/1	5/1/0	6/0/0	11 (1–24)

Group II	12	68 (42–85)	5/7	5/1/1/5	5/1/6	2/2/8	62 (12–150)

Group III	11	56 (40–73)	5/6	4/0/1/6	7/3/1	4/5/2	9 (2–18)

Controls	10	42 (20–59)	5/5	6/0/4/0

Radiation accident victims	3	38 (27–48)	2/1	Estimated protracted dose [10]: 2.7; 0.5; 1.0 Gy

	Number of persons	Mean age (range) in years	Males/females	Smokers (non-/NA/current /ex)a	Steroid treatment (no/NA/yes)a	Non-steroidal anti-inflammatory drug (no/NA/yes)a	Mean duration of symptoms (range) in monthsb

Group III	11	56 (40–73)	5/6	4/0/1/6	7/3/1	4/5/2	9 (2–18)

Controls	10	42 (20–59)	5/5	6/0/4/0

Radiation accident victims	3	38 (27–48)	2/1	Estimated protracted dose [10]: 2.7; 0.5; 1.0 Gy


Cut-off	Sensitivity	Specificity	Positive predictive value	Negative predictive value


DNA amount [μg]	Plus reagent [μl]	Ratio lipid to DNA	Quality	Cells in suspension	Fluor. intensity	Transfection efficiency [%]

0.25	0.25	1.0:1	1	0	+	0.6

2.0:1	2	0	+	0.5

2.5:1	2	0	+	3.1

3.0:1	2	0	+	3.8


Primary outcome measures	Generic quality of life	SF-36

	Functional health status	FIM

Secondary outcome measures	Anxiety and depression	HADS

	Cognitive functioning	MMSE

	Extent to which individual ADL treatment goals are met	COPM

Note: Costs will be assessed using the PRODISQ, a cost questionnaire and hospital database data


Age (years)	Influenza A	Influenza B

Positive	Equivocal	Negative	Positive	Equivocal	Negative


Variable	Coefficient	Standard error	P-value	Relative risk (95% CI)

Multiple tumors	0.679	0.147	< 0.001	1.973 (1.478 to 2.633)

Macrovascular invasion	0.581	0.227	0.011	1.789 (1.145 to 2.793)

Edmondson-Steiner grade III to IV	0.419	0.147	0.004	1.521 (1.141 to 2.028)


12-month falls recall	Daily calendar

Falls, N (%)	No falls, N (%)


Inclusion criteria	Exclusion criteria

Age ≥ 18 years	History of previous major hepatic surgery (i.e. more than three liver segments) or biliary major surgery (except gall-bladder surgery by laparoscopy if more than 6 months previously)

Patients with liver metastases requiring a hepatectomy of ≥ 2 segments	Patients with cirrhosis or sinusoidal obstruction syndrome with portal hypertension

Eastern Cooperative Oncology Group performance status ≤ 1	Pregnant women

Adequate bone marrow and liver function at baseline (defined by platelet count ≥ 100 × 109/L, and haemoglobin of ≥ 9 g/dL, and total bilirubin ≤ 1.5 × upper limit of normal, and transaminases ≤ 5× upper limit of normal)

Recovered from prior anti-neoplasic treatment-related toxicity (grade <2 persistent treatment-related toxicity as per Common Terminology Criteria for Adverse Events v4 are accepted

Willingness for follow-up visits

Covered by a medical insurance

Signed and dated informed consent indicating that the patient has been informed of all aspects of the trial prior to enrolment


	First comprehension test(n = 30)	Second comprehension test(n = 35)

Items	Patients reporting difficulties in understanding items (%)	Patients reporting difficulties in understanding items (%)

4	6.7	0

9	6.7	0

15	0	5.7

	Patients reporting difficulties in understanding questions (%)	Patients reporting difficulties in understanding questions (%)

Demographic 1	30.0	0

Demographic 3	13.3	0

Demographic 4	6.7	0

	First comprehension test(n = 30)	Second comprehension test(n = 35)

4	6.7	0

9	6.7	0

15	0	5.7

	Patients reporting difficulties in understanding questions (%)	Patients reporting difficulties in understanding questions (%)

Demographic 1	30.0	0

Demographic 3	13.3	0

Demographic 4	6.7	0


1	F 5′-TATAGGTACCAATTTATGGCAGTCATTA-3′	Amplification

2	R 5′-ATATGAGCTCGCTGGCCCGTGGCTGGAT-3′

3	S 5′-GTCCTTTTCTAGTGTATTGTGTTTGTTAATATTTG-3′	A→G

4	Compl 5′-CAAATATTAACAAACACAATACACTAGAAAAGGAC-3′

5	S 5′-GCTCCCACTAATGTGGTATTTAACTTTTGAAAGATCTTTAG-3′	NFκB (−1537)

6	Compl 5′-CTAAAGATCTTTCAAAAGTTAAATACCACATTAGTGGGAGC-3′

7	S 5′-GCTTTAAATAATTCTACAATATTTTGTGTATTTTGC-3′	HNF-3

8	Compl 5′-GCAAAATACACAAAATATTGTAGAATTATTTAAAGC-3′

9	S 5′-CAGAAAATATCGGTAATAAAAAAAGTTAAAGATCTTC-3′	Pou-IV

10	Compl 5′-GAAGATCTTTAACTTTTTTTATTACCGATATTTTCTG-3′

11	S 5′-GGAGGCTCCCTCCCCCCCCTCCAGCGC-3′	Sp1 (−236)

12	Compl 5′-GCGCTGGAGGGGAGGGAGGGAGCCTCC-3′

13	S 5′-GACCCGGCGCAGCACACCAACCGCGAGCAGAAC-3′	Ets

14	Compl - 5′-GTTCTGCTCGCGGTTGGTGTGCTGCGCCGGGTC-3′

15	S 5′-CGCTGCGGGCGCTTGCTGCCAGAACCTTG-3′	Sp1 (−124)

16	Compl 5′-CAAGGTTCTGGCAGCAAGCGCCCGCAGCG-3′

17	S 5′-CTTAAAGCACAGCCCATCACAGTTTTCATCCAGC-3′	NFκB (−40)

18	Compl 5′-GCTGGATGAAAACTGTGATGGGCTGTGCTTTAA-3′

1	F 5′-TATAGGTACCAATTTATGGCAGTCATTA-3′	Amplification

2	R 5′-ATATGAGCTCGCTGGCCCGTGGCTGGAT-3′

3	S 5′-GTCCTTTTCTAGTGTATTGTGTTTGTTAATATTTG-3′	A→G

4	Compl 5′-CAAATATTAACAAACACAATACACTAGAAAAGGAC-3′

5	S 5′-GCTCCCACTAATGTGGTATTTAACTTTTGAAAGATCTTTAG-3′	NFκB (−1537)

6	Compl 5′-CTAAAGATCTTTCAAAAGTTAAATACCACATTAGTGGGAGC-3′

7	S 5′-GCTTTAAATAATTCTACAATATTTTGTGTATTTTGC-3′	HNF-3

8	Compl 5′-GCAAAATACACAAAATATTGTAGAATTATTTAAAGC-3′

9	S 5′-CAGAAAATATCGGTAATAAAAAAAGTTAAAGATCTTC-3′	Pou-IV

	Compl 5′-GAAGATCTTTAACTTTT

10	TTTATTACCGATATTTTCTG-3′

11	S 5′-GGAGGCTCCCTCCCCCCCCTCCAGCGC-3′	Sp1 (−236)

12	Compl 5′-GCGCTGGAGGGGAGGGAGGGAGCCTCC-3′

13	S 5′-GACCCGGCGCAGCACACCAACCGCGAGCAGAAC-3′	Ets

14	Compl - 5′-GTTCTGCTCGCGGTTGGTGTGCTGCGCCGGGTC-3′

15	S 5′-CGCTGCGGGCGCTTGCTGCCAGAACCTTG-3′	Sp1 (−124)

16	Compl 5′-CAAGGTTCTGGCAGCAAGCGCCCGCAGCG-3′

17	S 5′-CTTAAAGCACAGCCCATCACAGTTTTCATCCAGC-3′	NFκB (−40)

18	Compl 5′-GCTGGATGAAAACTGTGATGGGCTGTGCTTTAA-3′


 	Kappa	% Agreement	Interpretation (Landis and Koch [21])

DSM-IV

 BN	0.66	99%	Substantial

 BED	0.46	92%	Moderate

 EDNOS	0.55	86%	Moderate

DSM-5

 BN	0.66	99%	Substantial

 BED	0.42	91%	Moderate

OSFED

 Sub-BED	0.48	96%	Moderate

 PD	−0.01	97%	Poor

 NES 	0.14	91%	Poor

 Other	0.59	94%	Moderate

	Kappa

DSM-IV

BN	0.66

BED	0.46

EDNOS	0.55

DSM-5

BN	0.66

BED	0.42

OSFED

Sub-BED	0.48

PD	−0.01

NES	0.14

Other	0.59

% Agreement	Interpretation (Landis and Koch [21])

99%	Substantial

92%	Moderate

86%	Moderate

99%	Substantial

91%	Moderate

96%	Moderate

97%	Poor

91%	Poor

94%	Moderate


Home	Number of Occupant	Baby Age	Shared Room	Average Temp. of the Environment

Home 1	3	8 months	No	21°

Home 2	5	10 months	Yes	22.5°

Home 3	4	14 months	No	19°

Home 4	3	3 months	No	20.5°

Home 5	6	9 months	Yes	24.5°


Analyte

retinol

25-hydroxycholecalciferol

retinol acetate

α-tocotrienol

cholecalciferol

astaxanthin

lutein

zeaxanthin

cantaxanthin

E-β-apo-8′-carotenal

cryptoxanthin

13-Z-β-carotene

α-carotene

β-carotene

9-Z-β-carotene

5-Z-lycopene


Sl no. P.I.	year	State/UT	Setting	Age group	N	Prev. (%)

1. Jiloha [72]	1981	Haryana	rural	5-12	715	20.7

Used questionnaire (t) and reporting questionnaire for children (p), clinical interview. Diagnosis was made as per ICD-9.

2. Devsigamani [22]	1990	TN	urban	8-12	755	33.7

Rutter B scale was used as a screening instrument and diagnosis was made as per ICD- 9 after clinical interview.

3. Mehta [74]	1997	WB	rural	8-10	8-10	460

Rutter B scale (Hindi adaptation), Malin’s test of verbal intelligence, VSMS, Gessell’s drawing test were used. Diagnosis was made as per DSM-III-R.

4. Banerjee [75]	1997	WB	rural	8-10	460	33.33

Rutter’s B scale was used as screening instrument and ICD-9 was used to make the diagnosis

5. Gupta [73]	2001	Punjab	urban	9-11	957	45.6

Rutter’s B scale was used as screening instrument and ICD-10 was used to make the diagnosis

6. Malhotra [76]	2002	Chandigarh	urban	4-11	963	6.33

Rutter B scale, pre-school behaviour checklist, Childhood Psychopathology Measurement Schedule was used. Diagnosis was made as per ICD-10.

7. Bansal [77]	2011	Punjab	urban	10-15	982	20.2

Childhood Psychopathology Measurement Schedule was used and Diagnosis was made as per ICD-10.

Sl no. P.I.	year	State/UT	Setting	Age group	N	Prev. (%)

Used questionnaire (t) and reporting questionnaire for children (p), clinical interview. Diagnosis was made as per ICD-9.

2. Devsigamani [22]	1990	TN	urban	8-12	755	33.7

Rutter B scale was used as a screening instrument and diagnosis was made as per ICD- 9 after clinical interview.

3. Mehta [74]	1997	WB	rural	8-10	8-10	460

Rutter B scale (Hindi adaptation), Malin’s test of verbal intelligence, VSMS, Gessell’s drawing test were used. Diagnosis was made as per DSM-III-R.

4. Banerjee [75]	1997	WB	rural	8-10	460	33.33

Rutter’s B scale was used as screening instrument and ICD-9 was used to make the diagnosis

5. Gupta [73]	2001	Punjab	urban	9-11	957	45.6

Rutter’s B scale was used as screening instrument and ICD-10 was used to make the diagnosis

6. Malhotra [76]	2002	Chandigarh	urban	4-11	963	6.33

Rutter B scale, pre-school behaviour checklist, Childhood Psychopathology Measurement Schedule was used. Diagnosis was made as per ICD-10.

7. Bansal [77]	2011	Punjab	urban	10-15	982	20.2

Childhood Psychopathology Measurement Schedule was used and Diagnosis was made as per ICD-10.


	BUN(mg/dL)	Creatinine(mg/dL)	Na+(mEq/L)	K+(mEq/L)	Cl−(mEq/L)	HCO3−(mEq/L)

Saline/Control	24.7 ± 1	0.25 ± 0	147.3 ± 1	3.8 ± 0	94.1 ± 1	22.7 ± 0

BC-NE	4	0.45	135.			23.7 ±


Year	Total sniffers	Sniffer prevalence rate per 1000 population


Cognitive domain	Age group	Standardised mean difference (95% CI)	Number of participants/studies	Heterogeneity - I2 test

Attention & concentration	Children aged 6-18	0.62 (0.26 to 0.98)*	132/2 (4 arms)**	0%

	Pre-menopausal women	0.53 (-0.06 to 1.12)	47/1	Not relevant

Intelligence	Children aged 6-18	0.02 (-0.22 to 0.27)	2289/4 (9 arms)**	82%

	Pre-menopausal women	0.62 (0.15 to 1.10)*	76/2	0%

Memory	Children aged 6-18	0.33 (-0.19 to 0.85)	132/2 (4 arms)**	35%

	Pre-menopausal women	0.09 (-0.31 to 0.50)	123/3	18%

Psychomotor	Children aged 6-18	0.19 (-0.17 to 0.54)	132/2 (4 arms)**	0%

	Pre-menopausal women	0.09 (-0.32 to 0.50)	123/3	21%

Scholastic aptitude	Children aged 6-18	0.03 (-0.63 to 0.69)	1799/3 (6 arms)**	96%

	Pre-menopausal women	0.77 (-0.08 to 1.62)	25/1	Not relevant

Cognitive domain	Age group	Standardised mean difference (95% CI)	Number of participants/studies	Heterogeneity - I2 test

Attention & concentration	Children aged 6-18	0.62 (0.26 to 0.98)*	132/2 (4 arms)**	0%

	Pre-menopausal women	0.53 (-0.06 to 1.12)	47/1	Not relevant

Intelligence	Children aged 6-18	0.02 (-0.22 to 0.27)	2289/4 (9 arms)**	82%

	Pre-menopausal women	0.62 (0.15 to 1.10)*	76/2	0%

Memory	Children aged 6-18	0.33 (-0.19 to 0.85)	132/2 (4 arms)**	35%

	Pre-menopausal women	0.09 (-0.31 to 0.50)	123/3	18%

Psychomotor	Children aged 6-18	0.19 (-0.17 to 0.54)	132/2 (4 arms)**	0%

	Pr	0.09 (-0.32 to 0.5	123/3	2

Cognitive domain	Age group	Standardised mean difference (95% CI)	Number of participants/studies	Heterogeneity - I2 test

	e-menopausal women	0)		1%

Scholastic aptitude	Children aged 6-18	0.03 (-0.63 to 0.69)	1799/3 (6 arms)**	96%

	Pre-menopausal women	0.77 (-0.08 to 1.62)	25/1	Not relevant


Marshall score	 n (%)

1 No visible intracranial pathology	14 (13)

2 Cisterns present with midline shift 0-5 mm; no high or mixed density lesion > 25 ml.	36 (32)

3 Cisterns compressed or absent with midline shift 0-5 mm.	43 (39)

4 Midline shift > 5 mm;or surgically evacuated lesion;and non-evacuated high or mixed density lesion >25 ml	18 (16)

Marshall score	n (%)

4 Midline shift > 5 mm;or surgically evacuated lesion;and non-evacuated high or mixed density lesion >25 ml	18 (16)


Study site	Latitude	Longitude

Aimi (Ai)	35°20.9′ N	133°24.2′ E

Nawa (Nw)	35°30.0′ N	133°30.5′ E

Nakayama (Nk)	35°30.7′ N	133°33.9′ E

Akasaki (Ak)	35°27.8′ N	133°38.3′ E

Tohaku (Th)	35°29.3′ N	133°39.2′ E

Kurayoshi (Ku)	35°23.4′ N	133°44.7′ E

Togo (Tg)	35°28.0′ N	133°55.1′ E

Yura (YuA, YuB)*	35°28.5′ N	133°44.5′ E

Otsuka (Ot)	35°29.0′ N	134°09.1′ E

Kawahara (Ka)	35°23.5′ N	134°11.2′ E

Koge (Ko)	35°24.5′ N	134°19.9′ E

Fukube (Fu)	35°32.4′ N	134°15.4′ E

Study site	Latitude	Longitude

Aimi (Ai)	35°20.9′ N	133°24.2′ E

Nawa (Nw)	35°30.0′ N	133°30.5′ E

Na	35°30.7	133°33.9′

Study site	Latitude	Longitude

kayama (Nk)	′ N	E

Akasaki (Ak)	35°27.8′ N	133°38.3′ E

Tohaku (Th)	35°29.3′ N	133°39.2′ E

Kurayoshi (Ku)	35°23.4′ N	133°44.7′ E

Togo (Tg)	35°28.0′ N	133°55.1′ E

Yura (YuA, YuB)*	35°28.5′ N	133°44.5′ E

Otsuka (Ot)	35°29.0′ N	134°09.1′ E

Kawahara (Ka)	35°23.5′ N	134°11.2′ E

Koge (Ko)	35°24.5′ N	134°19.9′ E

Fukube (Fu)	35°32.4′ N	134°15.4′ E


		n(%)

Frontal	Left	4 (15%)

Right	4 (15%)

Temporal	Left	3 (11%)

Right	0 (0%)

Parieto‐occipital	Left	1 (3.8%)

Right	2 (7.7%)

Cerebellar	Left	3 (12%)

Right	5 (19%)

Vermis		3 (12%)

Brain stem		1 (3.8%)

Frontal

Temporal

Parieto‐occipital

Cerebellar

Vermis

Brain stem


	n Pla a 2	nPhl p 4	nJugr2

nPla a 2	nPla a 2 + rPla a 1	nPhl p 4	nPhl p 4 +Phl p1/Phl p 5/Phl p 6/Phl p 11	nJugr2	nJug r2 + rJugr1

Mean sIgE levels (ISU)	1.94	4.6	0.75	1.49	0.19	1.10

U Mann–Whitney sig.	0.00		0.00		0.00


Characteristic	Pneumonia

Probable Non-bacterial (n = 49)	Probable Bacterial (n = 54)	P Valuea

Age, mean (SD), mo	19 (10.5)	17.4 (11.6)	.14

Male sex, %	50%	51%	.90

Weight-for-age z score, mean (SD)	−1.03 (1.10)	−1.37 (1.21)	.24

Respiratory rate, mean (SD), respirations/min	57.0 (12.0)	62.6 (9.8)	.007

Oxygen saturation, mean (SD), %	96.3 (2.64)	92.84 (7.09)	<.01

WBC count, mean (SD), ×109/L	10.1 (6.42)	23.7 (10.6)	<.01

Hemoglobin, mean (SD), g/dL	10.3 (1.53)	8.65 (1.74)	<.01


TRa	Pathway name	Known pathway genes	Genes clustered with the TRb	TRE	Ref

betI (B1590)	glycine betaine synthesis	betABTI	betABTI	choline	[21]

catR (A2107)	benzoate degradation	catABCR	catABCR	cis, cis-muconate	[22]

cymR (A3550)	p-cumate catabolism	cymAaAbAcAdBCDEFHG	cymAaAbAcAd─CDE─ ─ ─	p-cumate	[23]

cysB (A2466)	sulfur metabolism	cysABPTWA	cysABPTW	N-acetyl-serine	[24]

glpR (A0643)	glycerol metabolism	glpABCDKFR	glp─ ─ ─DKFR	glycerol-3-phosphate	[25]

hpaR (B2027)	hydroxyphenylacetate catabolism	hpaGEDFHIR	hpaGEDFHIR	4-hydroxy-phenylacetate	[26]

kynR (A0736)	oxidative tryptophan degradation	kynABU	kynABU	L-kynurenine	[27]

hutC (A2946)	histidine degradation	hutHUIFGC	hutHUIFGC	urocanate	[28, 29]

rcoM (A2142)	carbon monoxide oxidation	coxBCMSLDEFGHIK	cox ─ ─SMLDE ─G ─ ─ ─	carbon monoxide	[30]

modEB2851)	molybdate transport	modABCDE	modABC─E	molybdenum	[31]

TRa	Pathway name	Known pathway genes	Genes clustered with the TRb	TRE	Ref

betI (B1590)	glycine betaine synthesis	betABTI	betABTI	choline	[21]

catR (A2107)	benzoate degradation	catABCR	catABCR	cis, cis-muconate	[22]

cymR	p-c	cymAaAbAcAd	cymAaAbAcAd─CDE─	p	[23]

TRa	Pathway name	Known pathway genes	Genes clustered with the TRb	TRE	Ref

 (A3550)	umate catabolism	BCDEFHG	 ─ ─	-cumate

cysB (A2466)	sulfur metabolism	cysABPTWA	cysABPTW	N-acetyl-serine	[24]

glpR (A0643)	glycerol metabolism	glpABCDKFR	glp─ ─ ─DKFR	glycerol-3-phosphate	[25]

hpaR (B2027)	hydroxyphenylacetate catabolism	hpaGEDFHIR	hpaGEDFHIR	4-hydroxy-phenylacetate	[26]

kynR (A0736)	oxidative tryptophan degradation	kynABU	kynABU	L-kynurenine	[27]

hutC (A2946)	histidine degradation	hutHUIFGC	hutHUIFGC	urocanate	[28, 29]

rcoM (A2142)	carbon monoxide oxidation	coxBCMSLDEFGHIK	cox ─ ─SMLDE ─G ─ ─ ─	carbon monoxide	[30]

modEB2851)	molybdate transport	modABCDE	modABC─E	molybdenum	[31]


Compounds	Content (μg/g of dry plant material weight)	Approximate RT (min)

	MTa	MGa	MOKa

phenolic acids

Hydroxyphenyl acetic acid	914.26 ± 3.42	2053.42 ± 532.2	ndb	2.425

gallic acid	723.19 ± 4.1	744.72 ± 12.1	2780.57 ± 492.1	6.0

syringic acid	119.31 ± 4.2	148.45 ± 33.3	-	14.35

Ferulic acid	250.18 ± 3.2	41.64 ± 6.2	4657.94 ± 840.1	24.66

Methyl galate	Nd	229.84 ± 99.2	nd	3.61

Vanillic acid	1189.39 ± 973.3	614.72 ± 41.2	nd	15.96

Hydroxybis	132.2 ± 0.3	5581.77 ± 531.7	nd	3.69

Compounds	Content (μg/g of dry plant material weight)	Approximate RT (min)

	MTa	MGa	MOKa

flavonoids

Tyrosin	5013.06 ± 934.1	59.48 ± 3.9	nd	5.85

flavone	128.6 ± 0.4	65.65 ± 9.6	5512.01 ± 372.2	9.16

Vanillin	1079.26 ± 57.1	126.08 ± 15.8	nd	17.56

(+)- Catechin hydrate	18.01 ± 0.22	4.9 ± 0.7	nd	19.68

Rutin	609.62 ± 0.6	88.54 ± 2.8	nd	23.65


Variables	Tertiles of plasma manganese concentrations (μg/L)

1 (Lowest) ≤ 4.21 μg/L	2 4.21–6.84	3 (Highest) ≥ 6.84 μg/L

n(NGT/T2D)	538/780	541/377	535/457

Crude	2.08 (1.75, 2.47)	1	1.23 (1.02, 1.47)

Model 1	2.08 (1.73, 2.49)	1	1.28 (1.05, 1.55)

Model 2	2.15 (1.75, 2.63)	1	1.54 (1.23, 1.92)

Model 3	1.89 (1.53, 2.33)	1	1.56 (1.23, 1.97)

Model 1, adjusted for age, sex, and body mass index. Model 2, adjusted for Model 1, current smoking status, current alcohol drinking status, physical activity, family history of diabetes, and hypertension. Model 3, adjusted for Model 2, plasma iron, plasma copper, and plasma selenium.


Mean age in years (SD)

Mean BMI (SD)

Gender, % (No)

Male

Race, % (No)

Caucasian

Mixed

All other

Rank, % (No)

Lower enlisted

Senior NCO

Officer

Sleep diagnoses, % (No)

OSA

Insomnia

OSA + insomnia

None

Depression severity (QIDS)

PTSD severity (PCL-M)

Prescribed medications, % yes (no)

SSRI

Prazosin

Anti-hypertensive


	Avg Wait Time

	in Hours

Monday	0.7609

Tuesday	0.7284

Wednesday	0.6218

Thursday	0.5672

Friday	0.5127

Saturday	0.3954

Sunday	0.3858


Outcome	Improved	Deteriorated	No change	N

Caregiver burden (ZBI)	0	4	13	17

Hopefulness (HHI)	3	8	6	17

Anxiety (HADS)	2	0	15	17

Depression (HADS)	1	1	15	17


Grou	Gend	Age 	Disease cou	B	FBG (mmol	HbA1	TC	LD	FPG 	TG (	BU	F	C	H


Items	MS1 T1	M2 T1	p	Ms1 T2	MS2 T2	p	MS3 T3	MS4 T3	p

How important are the following factors in considering your career in medicine?

Opportunities to make a difference in people’s lives	4.89	4.83	NS	4.88	4.83	NS	4.71	4.66	NS

Intellectual climate	4.41	4.52	NS	4.41	4.47	NS	4.23	4.13	NS

Desire to do primary care	3.04	2.74	.062	3.03	2.75	.074	3.04	2.88	NS

Availability of jobs	3.55	3.86	.032*	3.54	3.84	.44*	4.26	3.90	.025*

Job security	3.80	4.03	.099	3.80	4.00	NS	4.40	4.30	NS

Opportunity to help patients who are socially disadvantaged	4.71	3.89	.034*	4.15	3.90	.051*	3.84	3.51	.060

Desire to serve my community	4.42	4.32	NS	4.39	4.33	NS	4.23	3.66	<.001*

High income potential	2.82	3.36	<.001**	2.82	3.32	<.001**	3.45	3.25	NS

Job satisfaction	4.76	4.75	NS	4.77	4.77	NS	4.84	4.78	NS

Status of physicians	2.69	2.97	.088	2.65	2.86	NS	2.84	2.80	NS

How important are the following factors in considering your choice for a specialty?

Income expectations for the specialty	2.81	3.27	.002**	2.76	3.23	.001**	3.43	3.15	NS

Amount of education debt I have	2.81	3.04	NS	2.83	2.99	NS	3.30	3.09	NS

Ability to balance my work life with my family responsibilities	4.37	4.62	.013*	4.38	4.60	.026*	4.53	4.44	NS

Content of the specialty	4.69	4.70	NS	4.71	4.69	NS	4.59	4.70	NS

Competitiveness of the specialty	3.13	3.07	NS	3.11	3.06	NS	2.91	2.74	NS

Options for fellowship training associated with the specialty	3.25	3.47	NS	3.24	3.40	NS	3.51	3.58	NS

Length of residency training associated with the specialty	3.18	3.44	.080	3.17	3.48	.040*	3.48	2.98	.008**

The lifestyle of the specialty I am considering	4.20	4.42	.066	4.20	4.38	NS	4.36	4.16	NS

Prestige of the specialty I am considering	2.20	2.49	.042*	2.17	2.42	.072	2.41	2.59	NS

Career workshops and courses	2.66	2.53	NS	2.63	5.47	NS	2.71	2.36	.054*

Opportunities to do research in this specialty	2.58	2.42	NS	2.57	2.38	NS	3.37	3.10	NS

Opportunities to provide care to underserved populations	3.43	3.28	NS	3.41	3.28	NS	3.37	3.10	NS

Attitudes toward primary care

I would like to become a primary care doctor in the future.	3.12	2.97	NS	3.11	3.13	NS	3.13	2.62	.024*

I am more interested in learning the skills required for my chosen specialty rather than a general set	2.79	2.82	NS	2.75	2.69	NS	2.69	3.45	<.001*

Primary care knowledge is useful for all medical students.	4.75	4.68	NS	4.75	4.70	NS	4.70	4.75	NS

Primary care should be a patient’s first contact with the health care system.	4.39	4.36	NS	4.38	4.68	NS	4.68	4.47	.060

Medical interviewing is a fundamental tool for all medical students to learn.	4.89	4.83	NS	4.92	4.87	.062	4.87	4.88	NS

Preventative care knowledge is essential for all medical students to learn.	4.83	4.53	<.000**	4.85	4.70	<.001**	4.70	4.67	NS

It is essential that medical students learn how to best communicate with patients	4.89	4.86	NS	4.91	4.89	NS	4.89	4.87	NS

Primary care doctors mostly manage chronic health problems.	3.26	3.79	<.001**	3.25	3.89	<.001**	3.89	3.81	NS

It is impossible to be an expert in such a wide field as primary care	2.69	3.0	.035*	2.69	2.97	.016*	2.97	3.31	0.76

Primary care is not very intellectually stimulating	1.90	2.22	.010*	1.91	2.47	.014*	2.47	2.58	NS

Primary care doctors have a large work overload.	3.63	3.95	.006**	3.63	4.15	.005**	4.15	4.05	NS

Primary care doctors are poorly valued by the rest of the medical profession.	3.48	3.76	0.22*	3.49	3.78	.033*	3.78	3.77	NS

A primary care doctor is clinically competent to provide most of the health care an individual may	3.96	3.99	NS	3.94	4.36	NS	4.36	4.36	NS

Items	MS1 T1	M2 T1	p

How important are the following factors in considering your career in medicine?

Opportunities to make a difference in people’s lives	4.89	4.83	NS

Intellectual climate	4.41	4.52	NS

Desire to do primary care	3.04	2.74	.062

Availability of jobs	3.55	3.86	.032*

Job security	3.80	4.03	.099

Opportunity to help patients who are socially disadvantaged	4.71	3.89	.034*

Desire to serve my community	4.42	4.32	NS

High income potential	2.82	3.36	<.001**

Job satisfaction	4.76	4.75	NS

Status of physicians	2.69	2.97	.088

How important are the following factors in considering your choice for a specialty?

Income expectations for the specialty	2.81	3.27	.002**

Amount of education debt I have	2.81	3.04	NS

Ability to balance my work life with my family responsibilities	4.37	4.62	.013*

Content of the specialty	4.69	4.70	NS

Competitiveness of the specialty	3.13	3.07	NS

Options for fellowship training associated with the specialty	3.25	3.47	NS

Length of residency training associated with the specialty	3.18	3.44	.080

The lifestyle of the specialty I am considering	4.20	4.42	.066

Prestige of the specialty I am considering	2.20	2.49	.042*

Career workshops and courses	2.66	2.53	NS

Opportunities to do research in this specialty	2.58	2.42	NS

Opportunities to provide care to underserved populations	3.43	3.28	NS

Attitudes toward primary care

I would like to become a primary care doctor in the future.	3.12	2.97	NS

I am more interested in learning the skills required for my chosen specialty rather than a general set	2.79	2.82	NS

Primary care knowledge is useful for all medical students.	4.75	4.68	NS

Primary care should be a patient’s first contact with the health care system.	4.39	4.36	NS

Medical interviewing is a fundamental tool for all medical students to learn.	4.89	4.83	NS

Preventative care knowledge is essential for all medical students to learn.	4.83	4.53	<.000**

It is essential that medical students learn how to best communicate with patients	4.89	4.86	NS

Primary care doctors mostly manage chronic health problems.	3.26	3.79	<.001**

It is impossible to be an expert in such a wide field as primary care	2.69	3.0	.035*

Primary care is not very intellectually stimulating	1.90	2.22	.010*

Primary care doctors have a large work overload.	3.63	3.95	.006**

Primary care doctors are poorly valued by the rest of the medical profession.	3.48	3.76	0.22*

A primary care doctor is clinically competent to provide most of the health care an individual may	3.96	3.99	NS


Stigma	Medication adherence	Total	Statistics

	Non adherent	Adherent

	f	%	f	%

No perceived stigma	8	9.2	79	90.8	87	χ2 = 0.497

Experienced stigma	7	13.0	47	87.0	54	p = 0.481

Total	15	10.6	126	89.4	141	-


Model	Parameters	True value	Mean estimation	Estimated error

Three-way model

Case I	G-C/M-C/M-G	0.2	0.23	0.04

Case II	G-C/M-C/M-G	0.3	0.31	0.05

Case III	G-C/M-C/M-G	0.4	0.40	0.05

Independent model

Case I	G-C/M-C	0.2	0.22	0.04

Case II	G-C/M-C	0.3	0.31	0.05

Case III	G-C/M-C	0.4	0.43	0.04

Causal model

Case I	G-C/M-G	0.2	0.23	0.04

Case II	G-C/M-G	0.3	0.31	0.05

Case III	G-C/M-G	0.4	0.41	0.04

microRNA model

Case I	M-C	0.2	0.22	0.04

Case II	M-C	0.3	0.30	0.04

Case III	M-C	0.4	0.39	0.05


	Univariate OR (95 % CI)a

Sociodemographic

Intercept	–

Age: per 5-year increase	0.85 (0.77, 0.94)

Male	1.58 (1.07, 2.31)

Born in Canada	1.09 (0.62, 1.91)

Province of enrolment	–

British Columbia	Ref.

Ontario	0.50 (0.31, 0.81)

Quebec	0.45 (0.30, 0.65)

Otherc	0.24 (0.07, 0.84)

Aboriginal	1.75 (1.08, 2.82)

Heterosexual	1.52 (1.07, 2.16)

Living aloned	1.44 (1.09, 1.89)

Without a fixed addressd	2.19 (1.16, 4.14)

Recent changes in housing situatione	1.44 (1.06, 1.95)

Recent incarceratione	1.96 (1.14, 3.36)

Socioeconomic

Employmentd	0.34 (0.24, 0.49)

Average personal monthly income ($ CAD): per $100 increasee	0.96 (0.93, 0.99)

More than high school education	0.45 (0.30, 0.66)

Behavioral

Recent injection drug usee	2.79 (2.02, 3.85)

Marijuana used	1.82 (1.37, 2.42)

Cigarette used	1.67 (1.18, 2.35)

Alcohol used	1.28 (0.97, 1.67)

>5 alcoholic drinks per dayd	1.55 (1.06, 2.25)

Trading away foode,f	5.99 (3.53, 10.16)

Clinical

Taking cARTd	0.52 (0.31, 0.88)

Self-described health state—visual analogue scale (0–100): per 5-point increased	0.93 (0.89, 0.96)

Therapy for drug addictione	1.16 (0.79, 1.71)

Recent depressive symptoms (CES-D-10) (in the past week)	2.78 (2.06, 3.74)

Unmet healthcare needse	2.25 (1.55, 3.26)


Participant	TTD (Months)	FIGO stage	First attributions of illness symptoms

Retained condom	Intestinal worms	Genital infections (syphilis, gonorrhoea and Candida)	Menstrual problems (Menopause and other menstrual abnormalities)	Uterine swelling	No clue on cause	HIV and/or its complications	Cervical cancer	Other serious illness

P10	2	3B						X

P11	2	1A				X

P7	3	1A	X

P8	3	1B				X

P4	4	1B								X

P3	7	4A			X

P15	10	3B			X

P18	10	2A									X

P9	19	2A				X

P16	21	3B			X

P13	24	3A					X

P12	26	2A							X

P2	30	1B			X

P5	39	2B							X

P6	72	3B				X

P14	72	2B			X

P17	72	3B		X						x

P1	Missing	140			X

Participant	TTD (Months)	FIGO stage	First attributions of illness symptoms

Retained condom	Intestinal worms	Genital infections (syphilis, gonorrhoea and Candida)	Menstrual problems (Menopause and other menstrual abnormalities)	Uterine swelling	No clue on cause

P10	2	3B						X

P11	2	1A				X

P7	3	1A	X

P8	3	1B				X

P4	4	1B

P3	7	4A			X

P15	10	3B			X

P18	10	2A

P9	19	2A				X

P16	21	3B			X

P13	24	3A					X

P12	26	2A

P2	30	1B			X

P5	39	2B

P6	72	3B				X

P14	72	2B			X

P17	72	3B		X

P1	Missing	140			X

First attributions of illness symptoms

HIV and/or its complications	Cervical cancer	Other serious illness

	X

		X

X

X

	x


GeneID	Product Name	Locus	AMX*	CTC*	ENR*

1244239	ImpA	impA	-0.52	-0.53	4.55

1244433	DNA-binding protein Fis	fis	ns	ns	1.41

1244528	LexA repressor	lexA	ns	1.60	9.87

1244611	Hypothetical protein PM1264	-	-0.78	-0.57	ns

1244637	Transcriptional repressor protein MetJ	metJ	-0.53	-0.74	-0.80

1244659	Hypothetical protein PM1312	-	-0.56	-0.68	-0.31

1244737	DNA-directed RNA polymerase subunit alpha	rpoA	ns	-0.77	1.27

1244795	Hypothetical protein PM1448	-	-0.81	-0.70	1.29

1244828	Hypothetical protein PM1481	-	-0.53	-0.51	-0.51

1244993	Hypothetical protein PM1646	-	-0.62	ns	-0.70

1245061	Hypothetical protein PM1714	-	-0.74	-0.91	ns

1245083	DNA-directed RNA polymerase subunit beta'	rpoC	ns	-0.76	-0.87

1245184	ATP-dependent helicase HepA	hepA	-0.77	-0.77	1.69

1245314	DNA-binding transcriptional activator GutM	gutM	-0.55	-0.69	-0.62

1243539	Hypothetical protein PM0192	recJ	-0.77	-0.79	1.24

1243679	Hypothetical protein PM0332	recN	ns	ns	11.54

1243758	DNA-dependent helicase II	uvrD	ns	ns	4.26

1243814	DNA polymerase IV	dinP	-0.76	-0.83	1.83

1244020	Hypothetical protein PM0673	-	-0.63	-0.81	-0.47

1244323	Holliday junction DNA helicase B	ruvB	ns	-0.78	2.37

1244324	Holliday junction DNA helicase motor protein	ruvA	ns	ns	3.39

1244459	DeaD	deaD	-0.78	-0.72	-0.67

1244499	DNA repair protein RadC	radC	-0.52	-0.60	-0.65

1244507	DNA polymerase III subunit beta	dnaN	ns	ns	1.41

1244526	Primosomal replication protein N	priB	ns	ns	1.67

1244563	DNA polymerase III subunit delta	holA	ns	-0.88	1.38

1244666	MutY	mutY	-0.68	-0.86	1.17

1244774	RecQ	recQ	-0.86	-0.84	1.11

1244823	DNA gyrase subunit B	gyrB	ns	1.36	1.45

1245063	NAD-dependent DNA ligase LigA	ligA	-0.84	1.08	1.56

1245164	Recombinase A	recA	ns	ns	9.96

1245177	DNA mismatch repair protein	mutS	-0.87	-0.78	1.50

1245268	ATP-dependent RNA helicase RhlB	rhlB	-0.73	-0.83	1.07

1245298	Excinuclease ABC subunit A	uvrA	-0.78	ns	2.57

1243785	Hypothetical protein PM0438	ftsH	-0.94	-0.80	1.13

1244083	Hypothetical protein PM0736	DnaK	ns	-0.74	1.50

1244087	Hypothetical protein PM0740	dnaJ	-0.74	-0.79	1.29

1245051	ClpB	clpB	-0.66	ns	2.14

1245095	ATP-dependent protease ATP-binding subunit	hslU	-0.70	ns	2.58

1245163	Recombination regulator RecX	recX	-0.54	-0.78	6.44

GeneID	Product Name	Locus	AMX*	CTC*	ENR*

1244823	DNA gyrase subunit B	gyrB	ns	1.36	1.45

1245063	NAD-dependent DNA ligase LigA	ligA	-0.84	1.08	1.56

1245164	Recombinase A	recA	ns	ns	9.96

1245177	DNA mismatch repair protein	mutS	-0.87	-0.78	1.50

1245268	ATP-dependent RNA helicase RhlB	rhlB	-0.73	-0.83	1.07

1245298	Excinuclease ABC subunit A	uvrA	-0.78	ns	2.57

1243785	Hypothetical protein PM0438	ftsH	-0.94	-0.80	1.13

1244083	Hypothetical protein PM0736	DnaK	ns	-0.74	1.50

1244087	Hypothetical protein PM0740	dnaJ	-0.74	-0.79	1.29

1245051	ClpB	clpB	-0.66	ns	2.14

1245095	ATP-dependent protease ATP-binding subunit	hslU	-0.70	ns	2.58

1245163	Recombination regulator RecX	recX	-0.54	-0.78	6.44


Variable	Average interitem covariance	Number of items in the scale	Scale reliability coefficient

Distance	0.448	6	0.748

Positive	0.309	3	0.563

Demands	1.024	4	0.852

Variable	Average interitem covariance	Number of items in the scale

Distance	0.448	6

Positive	0.309	3

Demands	1.024	4

Scale reliability coefficient

0.748

0.563

0.852


Fragment	Size (bp)	Primer sequences (5'-3')

NC1	2573	FP: GATCCTGGGCCCCACATCCATCCTC

		RP: GATCGAATTCGCCCGGGAGGCCAGGGTCG

NC2	524	FP: GATCGAATTCGGCGAGAAGGGAGAAGCTGC

		RP: GATCAAGCTTTCAGTCCTGGGCAGTACCTGT

Primer sequences (5'-3')

FP: GATCCTGGGCCCCACATCCATCCTC

RP: GATCGAATTCGCCCGGGAGGCCAGGGTCG

FP: GATCGAATTCGGCGAGAAGGGAGAAGCTGC

RP: GATCAAGCTTTCAGTCCTGGGCAGTACCTGT


Heavy Metal	Arsenic (47)	Cadmium (34)	Mercury (30)	Lead (29)

Year	2012 (16), 2011 (16)	2009 (4), 2013 (4), 2014 (4)	2016 (9), 2013 (5), 2015 (5)	2016 (5), 2002 (4), 2006 (3), 2013 (3)

Product category	feed materials (18), pet food (12)	feed additives (10), feed materials (9), animal nutrition (obsolete) (7)	feed materials (13), pet food (9)	animal nutrition (obsolete) (8), feed materials (7), feed additives (6), feed for food-producing animals (obsolete) (5)

Notifying country	Italy (10), Germany (8), Belgium (7), Austria (5), United Kingdom (5)	Belgium (8), Germany (4), Norway (4)	Italy (14), Spain (5), Germany (4)	Netherlands (6), Germany (5), Belgium (4)

Origin country	Thailand (11), Poland (5)	China (8), Spain (4)	Thailand (10), Russia (5), Spain (4)	Netherlands (5), Spain (4), Turkey (3)

Notification basis	official control on the market (21), border control—consignment detained (12), company’s own check (11)	company’s own check (14), official control on the market (14)	official control on the market (14), border control—consignment detained (12)	company’s own check (12), official control on the market (10)

Notification type	alert (13), border rejection (12), information for follow-up (11)	information (12), information for follow-up (11)	border rejection (12), information for follow-up (10)	alert (9), information for follow-up (9), information (8)

Distribution status	no distribution (11), distribution restricted to notifying country (8), distribution to other member countries (8), information on distribution not (yet) available (7)	distribution on the market (possible) (10), distribution to other member countries (10), distribution restricted to notifying country (8)	product not (yet) placed on the market (11), distribution restricted to notifying country (7), no distribution from notifying country (6)	(not specified) (7), distribution on the market (possible) (6), distribution to other member countries (6), distribution restricted to notifying country (5)

Risk decision	undecided (37)	undecided (25)	not serious (18)	undecided (21)

Action taken	re-dispatch (8), withdrawal from the market (7), destruction (4), informing recipients (4), official detention (4)	withdrawal from the market (7), (not specified) (4), official detention (4), seizure (3)	re-dispatch (6), import not authorized (5), official detention (5), withdrawal from the market (5)	(not specified) (7), return to consignor (4), withdrawal from the market (4)

Heavy Metal

Year

Product category

Notifying country

Origin country

Notification basis

Notification type

Distribution status

Risk decision

Action taken

Arsenic (47)	Cadmium (34)	Mercury (30)	Lead (29)

2012 (16), 2011 (16)	2009 (4), 2013 (4), 2014 (4)	2016 (9), 2013 (5), 2015 (5)	2016 (5), 2002 (4), 2006 (3), 2013 (3)

feed materials (18), pet food (12)	feed additives (10), feed materials (9), animal nutrition (obsolete) (7)	feed materials (13), pet food (9)	animal nutrition (obsolete) (8), feed materials (7), feed additives (6), feed for food-producing animals (obsolete) (5)

Italy (10), Germany (8), Belgium (7), Austria (5), United Kingdom (5)	Belgium (8), Germany (4), Norway (4)	Italy (14), Spain (5), Germany (4)	Netherlands (6), Germany (5), Belgium (4)

Thailand (11), Poland (5)	China (8), Spain (4)	Thailand (10), Russia (5), Spain (4)	Netherlands (5), Spain (4), Turkey (3)

official control on the market (21), border control—consignment detained (12), company’s own check (11)	company’s own check (14), official control on the market (14)	official control on the market (14), border control—consignment detained (12)	company’s own check (12), official control on the market (10)

alert (13), border rejection (12), information for follow-up (11)	information (12), information for follow-up (11)	border rejection (12), information for follow-up (10)	alert (9), information for follow-up (9), information (8)

no distribution (11), distribution restricted to notifying country (8), distribution to other member countries (8), information on distribution not (yet) available (7)	distribution on the market (possible) (10), distribution to other member countries (10), distribution restricted to notifying country (8)	product not (yet) placed on the market (11), distribution restricted to notifying country (7), no distribution from notifying country (6)	(not specified) (7), distribution on the market (possible) (6), distribution to other member countries (6), distribution restricted to notifying country (5)

undecided (37)	undecided (25)	not serious (18)	undecided (21)

re-dispatch (8), withdrawal from the market (7), destruction (4), informing recipients (4), official detention (4)	withdrawal from the market (7), (not specified) (4), official detention (4), seizure (3)	re-dispatch (6), import not authorized (5), official detention (5), withdrawal from the market (5)	(not specified) (7), return to consignor (4), withdrawal from the market (4)


Location		Annual average hourly NO2 (μg/m3) based on the LUR estimate

	percent	min	max	mean	sd

Residences	100	6	56	28	8

 freeway/highway/arterial/ramp	17	15	56	34	9

 Collector	17	2	56	26	8

 local/strata/lane	66	2	56	26	8

 Rural	0.2	11	39	19	5


Name	First protein	Second protein	Sequence of the fusion helix

3,305	Protein A	mbp3–16	266*	QCAREAAREAAACD	13*

3,306	mbp3–16	Protein A	133	QCAREAAAREAACN	217

3,307	Protein A	mbp3–16	263	NCAQEAAAREAACD	13

3,308	mbp3–16	Protein A	129	ACILQAAAREAACN	217

3,309	Protein A	mbp3–16	266	QCAREAAARDLGCK	17

3,310	mbp3–16	Protein A	133	QCAREAAAREANCE	219

3,311	mbp3–16	Protein A	132	LCKNKAQQAAFYCI	227

3,312	mbp3–16	Protein A	125	NCRLAAILAKNKCQ	220

3,313	Protein A	mbp3–16	259	ACKLNAAQALGRCL	18

3,315	Protein A	mbp3–16	260	ACLNAAQAALGRCL	18

4,254	Protein A	mbp3–16	260	KCLNDALGAKLLCA	21

4,256	Protein A	mbp3–16	260	KCLNDAQAAKLLCA	21

4,257	Protein A	mbp3–16	259	ACKLNAAQALGRCL	18

4,258	Protein A	mbp3–16	259	ACKLNAAQAAGRCL	18

4,260	Protein A	mbp3–16	261	KCNDAAARALLECA	22

4,261	Protein A	mbp3–16	261	KCNDAALGAKLLCA	21

4,262	Protein A	mbp3–16	261	KCNDAAAGAKLLCA	21

6,758	Protein A	Calmodulin	260	KCLNDAEQIAEFCE	15

6,759	Protein A	Calmodulin	260	KCLNDEQIAEFKCA	16

6,760	Protein A	Calmodulin	259	ACKLNAQIAEFKCA	16

6,761	Protein A	Calmodulin	260	KCLNDAQAAAEECI	10

Name	First protein	Second protein	Sequence of the fusion helix

4,256	Protein A	mbp3–16	260	KCLNDAQAAKLLCA	21

4,257	Protein A	mbp3–16	259	ACKLNAAQALGRCL	18

4,258	Protein A	mbp3–16	259	ACKLNAAQAAGRCL	18

4,260	Protein A	mbp3–16	261	KCNDAAARALLECA	22

4,261	Protein A	mbp3–16	261	KCNDAALGAKLLCA	21

4,262	Protein A	mbp3–16	261	KCNDAAAGAKLLCA	21

6,758	Protein A	Calmodulin	260	KCLNDAEQIAEFCE	15

6,759	Protein A	Calmodulin	260	KCLNDEQIAEFKCA	16

6,760	Protein A	Calmodulin	259	ACKLNAQIAEFKCA	16

6,761	Protein A	Calmodulin	260	KCLNDAQAAAEECI	10


	Number of filled prescriptions	Switching between different statins

	≥ 2 filled statin prescriptions	No switches	1-3 switches

	N	Mean (%)	95% CI	N	Mean (%)	95% CI	N	Mean (%)	95% CI

Entire study population

Simvastatin users with generic substitution	94525	90.1	89.9-90.3	93572	86.9	86.0-87.8	7423	83.1	82.0-84.1

Simvastatin users with active decline of generic substitution	697	79.8	84.7-86.8	533	68.1	56.4-79.9	268	80.2	74.6-85.7

Simvastatin users not exposed to generic substitution	2911	52.5	76.6-83.0	5651	49.3	45.7-52.9	1292	75.9	73.4-78.5

Atorvastatin users	6616	85.8	50.9-54.0	6172	79.6	76.2-83.1	1359	67.0	64.6-69.5

Those with generic substitution

Generic substitution at first purchase	57844	88.7	88.4-89.1	59175	83.7	83.0-84.4	5139	80.7	79.6-81.8

Generic substitution later on	36681	92.2	91.8-92.5	34297	92.4	91.4-93.4	2284	88.4	86.8-90.1

	Number of filled prescriptions	Switching between different statins

	≥ 2 filled statin prescriptions	No switches	1-3 switches

	N	Mean (%)	95% CI	N	Mean (%)	95% CI	N	Mean (%)	95% CI

Generic substitution at first purchase	57844	88.7	88.4-89.1	59175	83.7	83.0-84.4	5139	80.7	79.6-81.8

Generic substitution later on	36681	92.2	91.8-92.5	34297	92.4	91.4-93.4	2284	88.4	86.8-90.1